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Abstract  
 
Type 2 diabetes is a metabolic disorder associated with chronic hyperglycaemia 
and hyperlipidaemia, with consequent insulin resistance and a progressive 
deterioration of pancreatic β cell mass and function. The combined deleterious 
effects of these metabolic changes on β cell are known as glucolipotoxicity (GLT). 
Alternative splicing is a post-transcriptional process that allows a single gene to 
encode multiple transcripts and is a crucial mechanism for generating proteomic 
diversity. However, little is known about the role of alternative splicing in diabetes. 
The aim of this study was to test whether metabolic conditions relevant to type 2 
diabetes affect alternative splicing in β cells. 
 
INS1 β cells were treated under GLT or control conditions and the expression of 
a panel of genes important for the regulation of alternative splicing was examined 
by quantitative reverse transcriptase PCR (RT-qPCR). These experiments 
showed that GLT conditions significantly increase expression of the stress-
associated mRNA processing and stability gene Elavl1 in β cells (p=0.04, n=4 
independent experiments). The role of Elavl1 in β cells is not known, but it has 
been shown previously that siRNA knockdown of the related family member, 
Elavl4, increases β cell apoptosis, suggesting that this family of genes regulates 
β cell survival.  Using a combination of exon arrays and a candidate gene 
approach, we have further shown that the increased Elavl1 expression in β cells 
by GLT conditions is associated with alternative splicing of apoptosis genes, 
including a variant of the TCF7L2 gene thought to induce β cell apoptosis. 
 
This suggests that the metabolic conditions existing in many people with type 2 
diabetes may cause aberrant alternative splicing in β cells increasing 
susceptibility to apoptosis and subsequent β cell loss. 
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1 Chapter 1- Introduction 
 
1.1 A brief history and introduction to diabetes 
 
Diabetes Mellitus (DM) is a complex heterogenous group of metabolic conditions 
characterized by hyperglycaemia resulting from impairment in insulin secretion, 
insulin action, or both (ADA, 2005; Das and Elbein, 2006). The pancreatic β cell 
and its secretory product insulin are central in the pathophysiology of diabetes 
(Atikson and Elisenbarth et al, 2001). The potential complications of T2D are 
heart disease and long-term damage, to different organs including the eyes, 
kidneys, the heart, nerves and blood vessels (WHO, 1999). Diabetes mellitus has 
become one of the main threats to human health in the 21st century (Zimmet et 
al, 2000) and is adding a huge cost to health care systems.  
 
According to the American Diabetes Association (1997) and World Health 
Organisation (1999), there are two major types of diabetes: 
Type 1 diabetes (T1D) results from the cell-mediated autoimmune destruction of 
pancreatic β-cells. Exogenous insulin is currently required for survival to prevent 
the development of ketoacidosis, coma and death (Piya and Michels, 2012). It is 
a complex, multifactorial disease caused by the interaction of genetic and poorly 
defined environmental factors. T1D occurs mainly in children and young adults 
and accounts for about 10 percent of diabetes cases (ADA Expert Committee, 
1997). The incidence of T1D has doubled in last two decades (Harjutsalo et al, 
2005; Harjutsalo et al, 2008, Chen et al, 2011). 
 
Type 2 diabetes (T2D) is the most common form of diabetes and is characterized 
by insulin resistance and either the dysfunction or loss of pancreatic β cells. The 
development of these abnormalities is not fully understood (WHO, 1999).  People 
with T2D can often control the disease with a combination of diet, exercise and 
non-insulin drugs for example, to enhance insulin sensitivity, though insulin is 
required in some cases.  Insulin resistance and T2D are strongly associated with 
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age, obesity and physical inactivity and may remain undiagnosed for several 
years where hyperglycaemia is not severe enough to cause clinical symptoms. 
These individuals are, however, at increased risk of developing macrovascular 
and microvascular complications. 
 
The prevalence of T2D varies in different racial/ethnic subgroups (Weyer et al, 
2001). Candidate gene association and genome-wide association studies 
(GWAS) have identified many diabetes susceptibility loci associated with T2D 
corresponding in many cases to genes that impact glucose induced insulin 
secretion, and include: TCF7L2, CAPN10, HNF4α, PTPN1, ADAMTS9, FOX01, 
HNEX, APOB etc (Sladek et al, 2007; Imamura and Maeda, 2011; Horikawa et 
al, 2000; Das and Elbein, 2006).   
 
According to the International Diabetes Federation (IDF), approximately 425 
million adults were living with diabetes in 2017 which will rise to 629 million by 
2045 and 352 million people were at risk of developing T2D. The proportion of 
people with T2D increasing in most countries (IDF Diabetes Atlas, 2017). This 
issue needs to be addressed urgently. 
 
1.2 Molecular and metabolic mechanisms of insulin resistance and β cell 
failure in T2D 
 
Insulin resistance can be defined as the inability of insulin to produce its usual 
biological actions at circulating concentrations that are effective in normal 
subjects. It can be caused by defects such as decreases in receptor 
concentration and kinase activity, and in the activity of intracellular enzymes 
(Pessin et al, 2000).  
Studies of T2D have shown that insulin secretion and insulin action control 
glucose homeostasis in a dual regulatory cycle: a rise in glucose concentration 
stimulates insulin secretion which lowers plasma glucose in a time and 
concentration manner. Additionally, sustained hyperinsulinemia inhibits insulin 
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secretion and insulin action (Ferrannini,1998). When genetic predisposition 
and/or an unhealthy lifestyle results in decreased insulin sensitivity, this is initially 
compensated for by an increase in β cell function or mass, so that glucose 
tolerance remains normal. When β cell function and insulin sensitivity both 
deteriorate, postprandial glucose tolerance becomes abnormal. At this point, β 
cell function is typically sufficient to maintain normal fasting plasma glucose 
concentration. As a result of further deterioration in β cell function and insulin 
sensitivity fasting glucose concentrations increase due to an increase in basal 
endogenous glucose production. Finally, because of further deterioration in β cell 
function, both fasting and postprandial glucose levels reach diabetic levels (Kahn, 
2001 and Weyer et al, 2001). The potential mechanisms by which the metabolic 
changes arise as a consequence of insulin resistance lead to β cell 
loss/dysfunction are discussed in section 1.4. 
 
1.3 Normal function of β cells in response to glucose 
 
Glucose stimulated insulin release is biphasic comprising a rapid first phase 
lasting 5-10 mins, followed by a prolonged second phase, which continues for the 
duration of the stimulus. In T2D both responses are diminished or blunted (Luzi 
et al,1989). The events which lead to the release of insulin from β cells are 
complex. The insulin released from the pancreas during first phase has been 
synthesized and stored in the secretory granules of β cells. In response to an 
increase in extracellular glucose, ATP levels increase causing closure of ATP-
sensitive potassium channels and depolarization of the β cell membrane. This 
results in an influx of calcium that triggers the exocytosis of insulin-containing 
granules and release of granule contents (Figure1.1). The second phase insulin 
release involves synthesis of new insulin molecules as well as ATP-dependent 
mobilization of granules from a storage pool into the rapidly releasable pool. 
Impaired pulsatile insulin secretion is an early marker of β cell dysfunction in T2D 
(Mitrakou et al, 1990). 
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1.4 Glucolipotoxicity of the pancreatic β cells 
 
Hyperglycaemia and elevated circulating free fatty acids (FFAs) are thought to 
contribute to β cell failure by causing cellular stress and ultimately β cell 
apoptosis, resulting in insulin insufficiency (Deborah et al, 2008). However, the 
underlying molecular and cellular mechanisms of glucolipotoxicity in T2D are still 
debated. 
 
Elevated FFAs in healthy individuals enhance insulin secretion but contribute to 
insulin resistance and progressive β cell failure in individuals with genetic 
predisposition to diabetes. Increased concentrations of saturated fatty acids are 
toxic to islet β cells (Montane et al, 2014). Palmitate is the most abundant 
saturated fatty acids in human plasma and its deleterious effects are mediated 
via ceramide mitochondrial apoptotic pathways (Maedler et al, 2001). 
Perturbations in mitochondrial permeability are observed early in the 
Figure1.1: Regulation of insulin secretion in the β-cell. Glucose enters the cell via the GLUT2 
receptor (in rodents). The glucose transporter in human beta cells is thought to be GLUT1 and 
GLUT3, it is GLUT2 in rodents (McCulloch et al, 2011). ATP levels increase by glucose metabolism 
which closes the ATP-sensitive channel, K+ATP, which depolarises the cell membrane and opens 
voltage-gated Ca2+ channel. As a result, Ca2+ action potentials are generated. An increase in the 
cellular Ca2+ is the triggering event that leads to exocytosis of secretory vesicles containing insulin. 
Image Reference, Novak, 2008. 
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development of fatty acid induced cell death in β cells (Koshkin in Poitout et al, 
2010). In rats and humans, both in vitro and in vivo, prolonged exposure of β cells 
to FFA inhibits glucose stimulated insulin secretion (Mason and Paolisso in 
Poitout et al, 2010). Furthermore, uncoupling protein 2 (UCP2), a mitochondrial 
carrier that regulates ATP production, is upregulated by prolonged elevation of 
FFAs, and is thought to also play a role in glucolipotoxicity (Joseph et al, 2004). 
 
However, further experiments have shown that exposure of rodent islets to high 
fatty acid conditions only impairs glucose-stimulated insulin secretion (GSIS) 
when the sugar concentration goes above a threshold concentration of 
approximately 8 mM (Muoio and Newgard, 2008). This suggests that β cell 
functional impairment is a consequence of the combination of elevated levels of 
both sugar and fatty acids, or glucolipotoxicity (GLT) rather than an exposure of 
either alone. 
 
According to this model (outlined in Figure 1.2), in the presence of simultaneously 
elevated levels of glucose and fatty-acid (FA), there is an increase in cytosolic 
malonyl-CoA and the formation of cataplerotic signals e.g. citrate. Since fatty acid 
synthase activity is lower than that of acetyl CoA carboxylase in the β cell, the 
predominant activity of malonyl-CoA is to inhibit carnitine-palmitoyl transferase-1 
(CPT-1) activity, which in turn blocks fatty acid oxidation and leads to 
accumulation of long-chain acyl CoA esters (LC-CoA) in the cytosol. 
Accumulation of cytosolic LC-CoA adversely affects β cell function. Transport of 
long-chain acyl-CoA (LC-CoA) in the mitochondria is reduced, and the 
esterification pathway is preferentially activated, leading to cytosolic 
accumulation of lipid-derived signalling molecules such as ceramide, diglycerides 
(DG), phosphatidic acid, phospholipids (PL) and triglycerides (TG). Therefore, 
fatty acid partitioning towards esterification and cellular lipid synthesis 
strengthens the cellular mechanism of glucolipotoxicity in β cells and the nature 
of the lipid derived metabolites are responsible for the deleterious effects (Prentki 
and Corkey, 1996; Poitout et al, 2010).  
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Figure 1.2: The permissive effects of glucose on the deleterious actions of fatty 
acids in pancreatic β cells. High sugar and fatty acids cause an increased cytosolic 
concentration of malonyl CoA which inhibits the enzyme carnitine palmitoyl transferase 
1. As a result, long chain acyl CoA (LC-CoA) are reduced in mitochondria and an 
esterification pathway is preferentially activated. It is the lipid metabolites that is 
responsible for their deleterious effects. 
 
Using the rat INS1 cell line, it has been shown that after exposure of β cells to 
high sugar and high fatty acid condition, there is a compensatory phase during 
which β cell proliferates which ultimately leads to increased insulin gene 
expression and secretion (Mason and Paolisso in Poitout et al, 2010, Sako in 
Poitout et al, 2010; Deborah et al, 2008). However, prolonged exposure of β cells 
to GLT conditions ultimately causes β cell failure and apoptosis (Jacqueminet in 
Poitout et al, 2010; Briaud in Poitout et al, 2010). A model showing the etiology 
of T2D in genetically susceptible individuals with excessive carbohydrate and fat 
intake is shown in Figure 1.3 (Prentki et al, 2002). 
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Figure1.3: Model illustrating the association of genetic predisposition and 
overnutrition in the etiology of T2D. In this model, genetically susceptible individuals, 
excessive carbohydrate and fat intake causes hyperinsulinemia along with increased 
hepatic lipoprotein secretion and elevated FFAs. This eventually causes insulin 
resistance in muscle and liver. On the other hand, excessive fuel allows β cell 
compensation by increased insulin secretion and β cell growth. The progressive rise in 
insulin resistance with altered β cell gene expression will lead to increase postprandial 
hyperglycaemia, which along with FFAs, will cause β cell failure and as a result of this 
changes in insulin secretion and β cell apoptosis diabetes emerges. Figure taken from 
Prentki et al, 2002. 
 
1.4.1 ER Stress 
 
It has been suggested that β cell failure may also be caused by activation of the 
unfolded protein response (UPR) and ER stress. When β cells are exposed to an 
increased secretory demand due to high sugar and overnutrition, the 
endoplasmic reticulum may struggle to cope with the increased rate of protein 
synthesis needed to maintain insulin secretion and blood glucose homeostasis, 
in ER stress (Cunha et al, 2008 and Bagnati et al, 2016).  
 
The molecular mechanisms by which glucolipotoxicity induced ER stress causes 
β cell death are not fully understood but may involve a depletion of ER Ca2+ stores 
(Cunha et al, 2008 and Bagnati et al, 2016) and involve in activation of ATF3, 
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CHOP, Jun N-terminal kinase (JNK), caspases 4 and 12, and the mitochondrial 
apoptosis pathway (Eizirik et al, 2008 and Chang-Chen et al, 2008). On the other 
hand, other studies suggest that high glucose levels only mildly activate ER stress 
signalling (Elouil et al, 2007). The long chain FFAs, palmitate and oleate, can 
induce ER stress via the activation of mitochondrial pathway of cell death through 
up regulation of pro apoptotic BCL-2 family member death protein 5 (DP5), 
(Oliveira et al, 2015). But the combined effect of FFAs and glucose can trigger β 
cells to activate apoptosis via any of the mechanisms described above such as 
UPR and/or the mitochondrial and oxidative stress etc.   
 
1.4.2 Limitation of glucolipotoxicity 
 
To define the cellular and molecular mechanisms of glucolipotoxicity, in vitro 
models using insulin-secreting cells are extremely valuable. But proper care 
should be taken when interpreting the results. For example, it is known that there 
are species-related differences in the sensitivity of β cells to fatty acid-induced 
cell death (Poitout et al, 2010). Using insulin-secreting cells and isolated islets, 
elevated glucose and fatty acid-induced β cell apoptosis can be observed after 
24h culture in human cells (El-Assad et al, 2003), whereas for rat cells 72h culture 
of β cells was not enough to induce apoptosis (Kelpe et al, 2003). However, due 
to this species related sensitivity, research results using model organisms should 
ideally be validated in human cells.  
Another limitation of using INS1 cells are that INS1 are proliferative, whereas 
native beta cells are not usually (Skelin et al, 2010). 
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1.5 Alternative Splicing 
 
1.5.1 Understanding of alternative splicing and its function 
 
Alternative splicing (AS) is a regulated process during gene expression that 
results in a single gene coding for multiple proteins (Black, 2003). In other way, 
many genes in higher eukaryotes encode RNAs that can be spliced in alternative 
ways to generate two or more different mRNAs and thus different protein products 
(isoforms). AS is a crucial mechanism for gene regulation and for proteomic 
diversity and markedly affects human development.  Its misregulation also 
underlies many human diseases (Zhou and Fou, 2013). Alternative splicing is 
achieved by exonic/intronic splicing enhancers/silencers (ESE, ISE, ESS, ISS) in 
combination with spatial and temporal expression of trans-acting splicing factors 
such as serine/arginine-rich (SR) proteins and heterogenous nuclear 
ribonucleoproteins (Zhou and Fou, 2013). It can be regulated at different stages 
of spliceosome assembly by different splicing factors and by many mechanisms 
that rely on cis-acting elements.  
 
Transcriptome analysis shows that 90% mammalian genes have several 
transcript isoforms along with around 160,000 alternative spliced transcripts that 
code for proteins. Those isoforms can potentially play an important role in disease 
(Webster, 2017). 
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Figure 1.4: Schematic presentation of different types of alternative splicing. 
Grey boxes represent constitutive exons and others are alternatively spliced exons or 
regions. Solid lines indicate introns and dashed lines are indicative of alternative 
pattern. Promoters are indicated by arrows and polyadenylation site by AAA. Types 
of alternative splicing are cassette exon, retained introns, mutually exclusive exons, 
use of alternative 5’ splice sites and alternative 3’ splice sites. 
Taken from ‘WormBook by Zahler, 
A. (2012). 
5’ splice site 3’ splice site 
Exon 1 Exon 2 
Pre-mRNA 
Intron 
Step 1 
Step 2 
GU          A              AG 
Branch site 
A              AG  
 
 
GU Intron Lariat 
5’ 
3’ 
A              AG  
 
GU 
Exon 2 Exon 1 
Exon 1-P-Exon2 
5’ 3’ 
5’ 
3’ 
Figure 1.5: The splicing reaction. Two transesterifications of splicing reaction in 
which phosphodiester linkage within the pre-mRNA are broken and new ones are 
formed; introns are removed in a form called a lariat.   
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There are numerous types of alternative splicing that can be observed, depending 
on the way exons are combined. The most frequently observed events are exon 
skipping or cassette exons, mutually exclusive exons, alternative donor or 
acceptor sites and intron retention. A schematic presentation of these alternative 
splicing events is shown in Figure 1.4. 
 
1.5.2 Mechanism of AS and its regulation 
 
The core splicing reaction consists of two successful transesterification reactions 
which involves two nucleophilic attacks on the phosphodiester bonds (Figure 
1.5). The first reaction is carried out by 2’-OH group of the branch point which is 
usually adenine and in the second reaction by 3’-OH group of the upstream exon.  
Splicing is carried out by an RNA-dependent molecular machine called the 
spliceosome, which consists of five small nuclear ribonucleoprotein particles 
(snRNPs) and a group of auxiliary proteins that cooperate to accurately recognise 
the splice site and catalyse the splicing reaction. Initially the 5’ splice site is 
recognised by small ribonucleoprotein U1 snRNP and the binding of splicing 
factor 1 (SF1) to the branch point in an ATP independent manner (E’ complex). 
The E’ complex converts in E complex by the binding of auxiliary factor U2AF to 
the polypyrimidine tract and the 3’ splice site AG. The E complex is then 
converted into ATP-independent pre-spliceosome A complex by a replacement 
of SF1 by U2 snRNP at the branch point. In constitutive splicing, U2 binds the 
branch point via SF3B1 (Holly et al, 2014). Further recruitment of the U4/U6-U5 
tri-SNP complex leads to the formation of the ATP dependent B complex, which 
is converted into catalytically competent splicing complex (Chen et al, 2010). The 
complex containing the pre-mRNA, and U1 and U2 snRNPs is called the pre-
spliceosomal complex and defines the introns when the size of introns are less 
than 250 nucleotides (Hertel and Berget in Webster, 2017). However, most 
introns are kilobases in length and it is thought that splicing in vivo requires 
interaction of U1 and U2 snRNPs across the exons rather than introns, a process 
termed as ‘exon definition’. This is followed by long range splice site pairing 
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across the intron to assemble the functional spliceosome (Figure 1.6); (Hertel and 
Berget in Webster, 2017). 
 
The interaction between cis-acting elements and trans-acting factors determines 
whether such exons will be present in the mature mRNA. Cis-acting elements 
include exonic splicing enhancers (ESEs) and intronic splicing silencers (ISEs) 
those are bound by positive trans-acting factors e.g. serine/arginine-rich (SR) 
family proteins, depending on their location and on how they affect the selection 
of a splice site. Conversely, exonic splicing silencers (ESSs) and intronic splicing 
silencers (ISSs) are bound by negative trans-acting factors e.g. heterogenous 
nuclear ribonucleoproteins (hnRNPs). The hnRNPs are extremely conserved 
from nematodes to mammals (Chen et al, 2010; Webster, 2017; Wang et al, 
2015). The interaction between the different components of the spliceosome 
specifically defines the alternative splicing of each exon (Pradas et al, 2014). 
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Figure 1.6: Molecular mechanisms of alternative splicing. The process begins with 
binding of U1 snRNA to the 5’splice site and the binding of splicing factor 1 (SF1) to the 
branch point by an ATP independent manner. The E’ complex converts in E complex by 
binding of auxiliary factor U2AF to polypyrimidine tract. E complex is then converted into 
ATP-independent pre-spliceosome A complex by a replacement of SF1 by U2 snRNP at 
the branch point. Tri-snRNP U4/U6-U5 lead to the formation of B complex. This complex 
contained all spliceosome subunit necessary for pre-mRNA splicing. The loss of U1 and 
U4 snRNPs and conformational changes catalytically active spliceosome C complex is 
formed. Exons are defined by binding of U1 and U2 snRNP across the exon in the 
primary transcript followed (Webster, 2017).  
 
1.5.3 Alternative splicing in ageing and disease 
 
Alternative splicing is essential in cellular growth, differentiation and tissue 
development. Many studies have found links between the altered expression of 
splicing factors to be associated with disease. For example, cancer is known to 
be associated with changes in AS, and these changes have been shown to 
contribute to disease progression (Sveen et al, 2016).  Data from mouse studies 
Taken from Chen et al, 
2010. 
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have shown that overexpression of SR proteins, Srsf1, Srsf3 and Srsf10 
transforms fibroblasts and increases tumour growth, and these proteins are also 
elevated in several human cancers. Besides the SR proteins, other RNA binding 
proteins e.g. hnRNPA1, hnRNPH, and PTB, which are hnRNPs, are 
overexpressed in cancer (Webster, 2017), suggesting that deregulated splicing 
of some splicing factors especially negative trans-acting factors (hnRNPs) or 
aberrant mRNA processing may associate with cancer in human and mice. By 
selecting a splice site more or less accessible to the spliceosome, hnRNPs 
regulate splicing reaction (Matlin et al, 2005). 
The strict regulation of AS is essential for physiological and pathological 
conditions and deregulation of this process is responsible for different chronic 
diseases and ageing (Latorre and Harries, 2017). Lee et al (2016) have shown 
that changes in splicing factors’ expression and regulation were associated with 
strain longevity in old and young mice in cellular model strain lifespan in spleen. 
They have also shown that splicing factors HNRNPA1 and HNRNPA2B1 were 
found to be associated in parental longevity in humans and changes isoform 
expression, specially hnRNP splicing inhibitor transcripts, helping in reducing 
cellular senescence and resuming the cellular proliferative capacity in long lived 
human model strains (Harries et al., 2011, Holly et al., 2013, Latorre et al., 2017, 
2018), suggesting that splicing factor expression is strongly associated with age 
and cellular senescence, and correct regulation may increase lifespan in mice 
and humans. 
There are several mechanisms, including AS of many cancer related genes, that 
caused the inactivation of oncogene suppression (Lamolle et al, 2006) or 
increase expression of some proteins resulting in cancer susceptibility or 
changed control over cell motility (Mazoyer et al,1998; Ghigna et al, 2005). A 
general loss of splicing fidelity changes the splicing profile which is the 
consequence of cancer-specific isoforms formation suggesting all these events 
may contribute to carcinogenesis (Brinkma, 2004).  For example, alteration of 
SFs regulation changes the gene expression profile in non-malignant cells have 
been confirmed by next generation sequencing. Some SFs are directly related to 
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cancer progression and acted as cancer biomarkers e.g. SRSF1 is a prototype 
splicing factor because of its connection between AS and cancer.  
 
As discussed above, normal regulation of SFs is hugely important for our normal 
physiology. Evidence suggests that dysregulated splicing is fundamental to 
cancer and neurodegeneration. Several spliced isoforms which are regulated by 
29 SFs are found to be related to Alzheimer’s disease (AD) where a reduction of 
splicing factors PTBP2, RAVER1 and an increase of ROD, PTBP1 are observed 
in brains from AD patients (Tollervev et al, 2011; Sato et al, 1999). SFs 
dysregulation also found to be reported in Parkinson’s disease (Beyer and Ariza, 
2013) suggesting changes in splicing regulation in the brain are responsible for 
some ageing related neurodegenerative diseases and these are associated with 
dysregulation of some negative trans-acting splicing factors (hnRNPs). 
 
Great progress has been made by studying individual transcripts and, more 
recently, through genome-wide approaches, which together provide a picture of 
the mechanistic regulation of alternative pre-mRNA splicing. Changes in 
alternative splicing have also been observed in myotonic dystrophy where 25 
novel aberrantly spliced exons were found (Yamashita et al, 2012), and in 
response to ionising radiation (Sprung et al, 2011). An exciting recent study in C. 
elegans showed that changes in splicing are associated with ageing, and that 
splicing factor1 (SFA1, Branch point binding protein) is essential for mediating 
the increased longevity associated with dietary restriction in this model organism 
(Heinz et al, 2017).  
 
AS is controlled by the actions between cis-acting factors and trans-acting 
regulators which resume normal gene expression in our body and it will be 
interesting to see how splicing factors expression modifies e.g. the SFs 
expression changes or splicing regulators themselves in altered metabolic 
conditions in T2D. 
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1.6 The role of TCF7L2 in diabetes 
 
TCF7L2 variants are associated with type 2 diabetes in multiple ethnic groups 
and it is the genetic risk factor with largest effect size for T2D (Cauchi et al, 2006; 
Sale et al, 2007; Scott et al, 2006 and Grant et al, 2006). But the understanding 
of functional mechanisms is largely elusive. Evidence that attenuation of TCF7L2 
activity is associated with isoforms formation which caused impaired beta cell 
function and apoptosis and may be a mechanism of beta cell failure in T2D (Le 
Bacquer, et al, 2011). The association may be because of the effect on TCF7L2 
transcription, splicing or polyadenylation (Locke et al, 2011). Most of the 
alternative splicing events reported for this gene are involved in 3’ splice site and 
research on the molecular diversity generated by AS may help to understand why 
this gene has emerged, since this gene has an association with T2D. 
 
1.6.1 TCF7L2 genomic variants are associated with the risk of T2D 
 
TCF7L2 is well known as an important transcription factor in the canonical Wnt 
signalling pathway that affects a wide range of fundamental cellular process e.g. 
embryonic development, stem cell maintenance, cell fate, cell proliferation, cell 
migration, tumour suppression, and oncogenesis.  In β cell, it also specifically 
plays a role in the regulation of insulin processing, secretion and β cell survival 
(Hanson et al, 2010).  
The TCF7L2 single nucleotide polymorphism (rs7903146) associates with T2D is 
located in intron 4 towards the 5’ end of the gene (Grant el al, 2006). Since this 
is within a non-coding region, the molecular mechanism of this association is not 
yet clear. It has been shown that expression of the risk allele is associated with 
impaired conversion of proinsulin to insulin (Loss et al, 2007 and Hansson et al, 
2010). However, other mechanisms have also been proposed. The risk allele is 
also associated with reduced insulin content and impaired glucose stimulated 
insulin secretion, as well as a reduction in glucagon-like peptide 1 (GLP-1; the 
incretin hormone main role in glucose homeostasis) (Hanson et al, 2010, 
Cropano et al, 2017, Pradas et al, 2014; Le Bacquer, et al, 2011). Locke et al 
(2011) also identified a novel polyadenylation signal within intron 4 of TCF7L2 
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that results in isoforms production which inhibits the full length TCF7L2 isoforms 
activity, full form TCF7L2 is involved in the pathogenesis of T2D and the relative 
use of this polyadenylation site in human tissues. The risk allele may therefore 
result in alternative splicing of TCF7L2, resulting in production of an inhibitory 
truncated isoforms inhibit TCF7L2-dependent target genes by sequestering β-
catenin. 
 
1.6.2 Expression of TCF7L2 isoforms in T2D  
 
A large-scale and complex splicing pattern of TCF7L2 AS was shown by Duval 
et al, (2000) and Hansson et al, (2010). The splicing pattern is different in different 
tissues (Hansson et al, 2010). Expression of the high-risk allele at the intronic 
rs7903146 has been shown to be associated with higher TCF7L2 mRNA 
expression (Lyssenko cited in Hansson et al, 2010), but lower protein expression, 
in donor (T2D) islets (Cauchi and Froguel cited in Hansson et al, 2010, Le 
Bacquer et al, 2011). As shown in Figure 1.8, there are two main regions that are 
alternatively spliced in β cells: (i) cassette exon 4, and (ii) cassette exons 13-16. 
 
 
 
Figure 1.7: Alternative splicing of TCF7L2 analysis in human islets. Four TCF7L2 
splice variants (A, B, C and D) are expressed in human pancreatic β cells. 
 
Image taken from Hansson et al, 2010 
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As discussed above, AS increases the functionally different isoforms. A recent 
study by Kaminska et al, (2012) has shown that a complex pattern of TCF7L2 is 
regulated by weight loss and associated with plasma glucose and serum FFAs 
along with obesity. The expression of a short mRNA variant, lacking exons 13, 
14 and 16, is associated with hyperglycaemia and impaired insulin action in 
adipose tissue which was more common in subcutaneous fat in T2D patients. 
The association between TCF7L2 splicing was independent of the TCF7L2 
genotype. The reason may be the impaired ability of this short mRNA variant to 
activate Wnt signalling in adipose tissue which, according to these researchers, 
induced beta cell apoptosis. They have shown that weight loss was associated 
with decreased expression of this short variants in adipose tissue in obese 
individuals. These findings may be important for in subjects with obesity which 
leading to increased diabetes risk. 
 
AS of exons 13-17 results in altered reading frames and can lead to transcription 
termination due to the introduction of stop codons (Kaminska et al, 2012; 
Hansson et al, 2010). The differential splicing results in several isoforms 
competing for promoter binding and thus shows different activation or repression 
properties (Weise et al, in Hansson, 2010). C-terminus is necessary for efficient 
TCF7L2/β-catenin activation of the target promoter (Weise et al in Hansson, 
2010). For example, the corepressor C-terminal binding protein (CtBP), an 
inhibitor of Wnt signalling pathway, and p300 are recognised by TCF7L2 long 
isoform (Duval cited in Hansson et al, 2010), suggesting the role of long isoform 
in beta cell survival. The sites CtBP interacts with are encoded by exon 17 and 
thus it inhibits TCF7L2 mediated expression, depending on the predicted stop 
codons are being used (Cuilliere-Dartigues cited in Hansson et al, 2010).  
 
Another study by Weise et al (2010), had shown that, in human, short transcript 
variants lacking the exons 13, 14 and 16 decrease the activation of β-catenin 
target gene promoters in Wnt signalling pathway in opposite to full length 
transcripts, isoform having exons 13, 14 and 16. Therefore, expression of short 
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variants lead to switch off the a chain of signalling events and thus function as 
inhibitor of Wnt signalling pathway.  
Therefore, AS in this 3’ region is crucial to maintain normal function of TCF7L2 
and alteration in splicing may lead to formation of isoforms which can lead to 
termination of TCF7L2 function and thus can impair β cell function, and lead to 
apoptosis. 
 
1.7 The wider role of alternative splicing in β cells 
 
Alternative splicing is a highly tissue-specific process, and only few studies have 
examined AS in β cells. Interestingly, one study has shown that a number of 
splicing regulators important in neurons are also expressed in β cells and regulate 
β cell survival and function (Mateu et al, 2017), specifically four RBPs (Elavl4, 
Rbfox1, Nova2 and Rbfox2). 
Knockdown of Rbfox1 using siRNA was shown to induce insulin secretion by a 
mechanism associated with alternative splicing of the actin remodelling protein 
gelsolin (Gsn) and the voltage-gated calcium channel 1C (Cacna1c). Splicing 
regulation of insulin receptor (Insr) was also modulated by Rbfox1 knockdown 
(Mateu et al, 2017). Another splicing regulator Nova1 has been reported to be a 
master regulator of AS in pancreatic β cells (Villate et al, 2014). It is expressed 
and regulates insulin secretion and apoptosis in β cells. Splicing factor Rbfox1 
controls the AS events of key genes (Gsn, Cacna1c and Insr) and which are 
involved in insulin secretion, gene expression, cell division and cell death (Mateu 
et al, Wong King Yuen et al, 2018). The AS events of these tissue specific splicing 
regulators are needing to explore in altered metabolic conditions to see their 
impact on β cells. 
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1.8 Aims 
 
We hypothesized that the metabolic conditions associated with type 2 diabetes 
may affect the regulation of alternative splicing. Although there is progress in 
understanding the molecular mechanisms in the pathogenesis of diabetes, little 
is currently known about the effect of metabolic changes that exist in many people 
with undiagnosed or uncontrolled diabetes on splicing in β cells, and how this 
may be linked to the decline in β cell mass and function. Therefore, the aim of 
this study was to determine the effects of metabolic conditions associated with 
T2D, specifically high levels of glucose and free fatty acids, on the regulation of 
alternative splicing. The specific aims of this project were: 
 
1. To determine the effect of high glucose and fatty acid conditions 
(glucolipotoxicity, GLT) on the expression of a panel of genes that regulate 
alternative splicing, using the rat INS1 cell line. 
2. Analyse the effect of GLT on alternative splicing of specific candidate genes 
e.g. Tcf7l2, Gsn and Cacna1c.  
3. To examine global changes in exon usage and splice junctions under GLT 
conditions in β cells using the Clariom D exon arrays. 
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Chapter 2- Materials and Methods 
 
2.1 Cell line and cell culture 
 
2.1.1 INS1 Cell line 
 
To study the effect of metabolic conditions on pancreatic β cells, INS1 cells was 
used, which are derived from a rat insulinoma that arose following irradiation 
(Asfari et al, 1992). INS1 cells were kindly donated by Dr Charlotte Edling of the 
Blizard Institute of Cell and Molecular Biology at Queen Mary University of 
London. 
After passage number 15, INS1 cells were not used for our experiments as they 
are very sensitive to environment and susceptible for mutation. There is a 
correlation between beta cell lines and phosphorylation of hexokinase activity 
which is key to glucose sensing and accurate insulin secretion. In cell culture, low 
Km value is observed for this glucose phosphorylating enzyme hexokinase, 
which is a deviation from normal phenotype that often β cell lines sustain during 
the first 20 passage in culture (Efrat, 1999). Therefore, cells were discarded after 
3 passages when they were received (passage number 12 was received) for our 
experiments. Mostly Passage number 13 was used for our GLT treatment. 
 
 
2.1.2 Cell culture media 
 
INS1 cells were maintained in RPMI 1640 medium (Sigma-R8758 series) 
containing 11.1mmol/l D-glucose supplemented with L-glutamine (Fisher 
Scientific), 10 mM HEPES buffer (Sigma), 1 mM Sodium-pyruvate (Sigma), 
100µg/µl penicillin-streptomycin (Fisher Scientific) and 0.05 mM 2- 
mercaptoethanol, and 10% Fetal Bovine Serum albumin (Gibco-10270-106; 
South American origin).  Serum free medium was of the same formulation except 
10% Fetal Bovine Serum (FBS) was added. 
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2.1.3 Cell storage and maintenance 
 
For long term storage, INS1 cells were stored at the vapour phase of liquid 
nitrogen (higher racks) at temperature between -140°C and -180°C. To remove 
cells from liquid nitrogen, the vial was first sprayed with 70% ethanol and cells 
were thawed until a small piece of frozen medium remained (2-3 mins). The cell 
suspension was transferred very slowly or dropwise into a filter capped T75 flask 
(Thermo Fisher Scientific) with 25-28 ml of complete medium. The medium was 
replaced with fresh complete medium the following day. Cells were cultured in a 
T75 flask and incubated at 37°C in a 5% CO2 atmosphere. 
 
2.1.4 Cell sub-culturing  
 
Cell lines were passaged when cells were 75-80% confluent. Growth medium 
was aspirated and discarded. Cells were briefly washed in five millilitre (ml) of 
sterile phosphate buffered saline solution (PBS), three ml of (1x) trypsin-EDTA 
solution (Sigma) was added and then incubated for approximately 4 minutes at 
37°C in 5% CO2 to detach cells, a process known as trypsinization. Cell 
detachment was observed using a bright field inverted microscope (Motic AE31). 
Seven ml complete medium was added to the flask and gently pipetted up and 
down a few times. An aliquot of three ml cell suspension was moved into a new 
T75 flask containing 24-28 ml medium.  
 
2.1.5 Cryo-preservation of INS1 cells  
  
When INS1 cells were 75-85% confluent they were used for preservation. Growth 
medium was aspirated, and cells were trypsinized as described above. Cells were 
resuspended in ten ml complete medium and centrifuged at 1000 rpm for 3 
minutes. Cell pellets were resuspended in one ml of complete media.  According 
to cell count, freezing media (3 ml of serum free RPMI 1640, 2 ml of 10% FBS, 
100 µg/ml Penicillin-Streptomycin) was filter sterilised (0.2 µm) and added to 
cells. All solutions using for cell preservation were stored on ice. A 20% DMSO 
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solution (100% DMSO-Sigma Aldrich, UK), was added dropwise to cell 
suspension and the total volume transferred in cryovials. Again, serum free RPMI 
1640 was used to make the DMSO solution. Cells were stored in freezer (-80°C) 
for at least 24h before being transferred in liquid nitrogen for long-term storage.  
 
2.1.6 Cell counting and seeding density 
 
As described in the above section 2.1.4, after trypsinisation ten ml of cell 
suspension was transferred to a 20 ml universal tube. After that the cell 
suspension was centrifuged for 3 minutes at 1000 rpm to pellet the cells. The 
medium as aspirated carefully without disrupting the cell pellet. Once removed, 
the pellet was disrupted by gently tapping the side of the tube and afterward cells 
were resuspended in 1 ml of fresh medium. Ten microliter (µl) of cell suspension 
was pipetted into an Eppendorf for cell counting.  Trypan blue was used to 
distinguish viable cells from dead cells and served as a diluent. Approximately 
ten µl of the cell-trypan suspension were inserted into a chamber of a disposable 
haemocytometer (#BSV100H, Immune Systems) for cell counting and the 
concentration of cell per ml was calculated using the following formula: 
 
Cells/ml = Average no of cells per large square x Dilution factor x 104 
 
To achieve a growth curve, INS1 cells were seeded for 24 hours at density of 
30,000 cells/well in a 96 (VWR) well plate, as described before (Viloria et al, 
2016). The culture media was aspirated and replaced with freshly prepared GLT 
and control media to appropriate wells of the 96 well plate. The plate then placed 
into the IncuCyte (Essen Bioscience) live cell analysis system and allowed the 
plate to warm to 37 °C for 30 minutes prior to scanning.  Cell growth was 
monitored using the Imaging system to determine cell area or cell confluency over 
the indicated time period, as describe in section 2.1.9. 
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2.1.7 GLT media 
 
To mimic in vivo diabetic extracellular glucolipotoxic conditions, INS1 cells were 
treated with 27mM glucose, 200 µM oleic acid (C18:1) and 200 µM palmitic acid 
(C16:0) in RPMI media (which contains 11mM glucose before supplementation).  
This is referred to as GLT treatment. In vitro exposure of high FFAs caused 
cellular dysfunction and death (Cnop, 2008). Although oleate can abrogate the 
effects of palmitate, it is more physiological to deliver a high FFAs solution which 
consists of palmitic acid and stearic acid as those two are the most common fatty 
acids in human. The experimental condition was adopted from Bagnati et al, 
2016. The GLT media was prepared on the day of use and filtered using 0.2µm 
filter prior to cell treatment. 
 
2.1.8 Free Fatty acid (FFA) conjugation 
 
Long chain fatty acids are important substrate for energy production, among them 
most common fatty acids in humans are the long-chain saturated fatty acid 
palmitate (C16:0) and the monounsaturated oleate (C18:1). The low solubility of 
long-chain fatty acids in aqueous solutions is one of the major limitations for in 
vitro and in vivo studies. To overcome this problem, FFAs were conjugated to 
albumin which allowed the preparation of solutions in the physiological 
concentration range (Oliveira et al, 2015).   
 
Palmitic acid (#P0500-10G; Sigma) was dissolved (100 mM) in absolute ethanol 
and oleic acid (#07501-250MG; Sigma) was dissolved (100 mM) in 50% ethanol 
(absolute ethanol was dissolved in distilled water in 1:1 ratio). To achieve 
solubility, vortexing was required for both solutions.  Both serum free and 
complete media were supplemented with two percent BSA (#A7030-10G; Sigma) 
to facilitate free fatty acids conjugation. Despite of 11 mM glucose in RPMI media, 
extra 16 mM glucose and fatty acids were added, so the total glucose was 27 
mM. The media was filtered (0.2 µm) and the solution was incubated for 1 hour 
at 37°C which facilitated free fatty acid conjugation with albumin. Cells were 
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subsequently treated with GLT media in both complete and serum free 
conditions. Controls were made with the corresponding amounts of ethanol and 
BSA.  
 
Glucolipotoxic media was prepared fresh for each day of use although the FFA-
albumin complexes can be prepared in large amounts and preserved for several 
years at -20°C.  
 
2.1.9 Image analysis using IncuCyte Zoom 
 
IncuCyte Zoom 2015A and 2016A software was used for the growth analysis in 
the following procedure: 
1) Open Schedule Scan from the Task list > click on the position- add your 
plate-choose vessel type. 
 
2) New processing definition—Training image collection- change 
‘segmentation adjustment’ bar to separate cells from background -select 
‘area (um2)’ under ‘filters’ and add a minimum value to exclude debris (250 
um2 was used in this study)-select ‘preview’- adjust further parameters if 
required to increase accuracy- select ‘preview’ again- ‘scratch wound 
mask’ and ‘confluence mask’ which will help visualize the experiment 
during this stage but will not change processing parameters. Once 
appropriate parameters have been chosen then save processing 
definition-File- ‘save as’- give a name. This can be used for further 
experiments and it is a requirement of the machine that one is selected to 
run the assay. 
 
3) Scan pattern-Choose scan pattern from the list -job type- ‘Basic 
Analyser’ 
 
4) Select ‘Properties Tab’-put experiment name-cell type-plate map-
passage no-then ‘APPLY’. 
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5) Launch Analysis Job-select ‘Scanned Vessel’ from Task List-choose 
experiment-job type- basic analyse-select processing definition-define 
time points you wish to use-select the wells- click ‘lock’. 
 
6) Exporting Results-Choose your analysis result from Task List-select 
‘Graph/Export’-choose ‘Metric’ you wish to export- select ‘Group’-select 
‘None’- you can see the microplate graph and print that out-click ‘Export’ 
which will export a txt file that can open in excel. 
 
7) To export images, select ‘image type’-Export- it will export images. 
 
8)  To export representative images- select’ utilities tab’- Export single 
image-select ‘phase contrast ‘select time, date and bar stamps-select 
‘continue’ begin export. 
 
 
2.2 RNA preparation and analysis 
 
2.2.1 RNA extraction 
 
For GLT treatment, INS1 cells were cultured at 30,000 cells/100µl in 6 well plate 
and allowed to adhere 24 hours, before treatment with GLT or control media for 
46 hours. For GLT experiment, four biological replicates were there with three 
technical replicates. 
RNA extraction was performed using RNeasy columns (Qiagen). Briefly, cells 
were lysed with the lysis buffer (RLT) and vortexed. An equal volume of 70% 
ethanol was added to the homogenized lysate and mixed well by pipetting and 
transferred to the RNeasy spin column. The solution was centrifuged at 10,000 
rpm for 15 seconds. To remove genomic DNA from RNA preparations DNase 
digestion was carried out by using the DNase I in RDD buffer according to the 
protocol.  A series of washes followed as an RNA purification process and each 
time the flow-through had been discarded. Finally, the purified RNA was eluted 
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from the spin column in 30 µl of RNase free water. RNA integrity and quantity 
were assessed using an Agilent Bioanalyzer or Nanovue spectrophotometer 
(discussed in detail in results chapter 4). For long term storage, RNA was stored 
in -80°C. 
Spectrophotometry provides both individual absorbance values and absorbance 
ratios.  RNA concentration is measured at absorbance of 260 nm where the light 
absorbed by a substance is directly proportional to the concentration of the 
substance (Beer-Lambert Law). RNA absorbs light at 260 nm whereas protein 
and ethanol absorb at 280 and 230 nm respectively. A ratio of 260/280 and 
260/230 is an indicative of RNA purity, a range in between 1.9-2.1 demonstrates 
that the RNA isolated was of high quality and purity. All RNA samples used in this 
experiment fell into this range.  
 
2.2.2 First strand cDNA synthesis 
 
cDNA synthesis was performed using RevertAid First Strand cDNA synthesis kit 
(Thermo Scientific) with 500ng of total RNA. The reaction (20 µl reaction) set up 
with reverse transcriptase (RT), no reverse transcriptase control (NRT) and no 
template control (NTC) is shown in Table2.1.  All reaction tubes were incubated 
on ice while performing the reaction. Table 2.2 shows the PCR cycling conditions 
for reverse transcription. The oligo d(T) method was used, with total RNA as a 
template. 
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           Table 2.1: PCR reaction for reverse transcription. 
Reagents  RT  
(master 
mix) 
NRT  
(master 
mix) 
NTC 
(master 
mix) 
Total RNA 500 ng 500 ng Not 
applicable 
Oligo (dt)18 primer 0.3 µM 0.3 µM 0.3 µM 
Water, nuclease-free To 12 µl To 12 µl To 12 µl 
5x Reaction Buffer 4 µl 4 µl 4 µl 
RiboLock RNase 
inhibitor (20 U/ µl) 
1 µl 1 µl 1 µl 
10 mM dNTP Mix 2 µl 2 µl 2 µl 
RevertAid M-MuLV 
RT (200 U/ µl) 
1 µl Not 
applicable 
1 µl 
                 
           
2.2.3 RT- PCR 
 
 Polymerase Chain Reaction is a technique that used to amplify a specific 
segment of DNA from a small amount of DNA template. Dream TaqTM (Thermo 
Fisher Scientific) was used and is a ready to use master mix buffer supplemented 
with MgCl2, dNTPs, two tracking dyes and a density reagent that allows direct 
loading of the PCR product on a gel. A thermal cycler is to maintain a series of 
temperature for a set amount of time (Table 2.2).  
 
           Table 2.2: Standard PCR Cycling Condition. 
Initial 
Denaturation 
Stage 1 (1 Cycle) 95°C for 2 mins  
Denaturation  
Annealing 
Extension 
Stage 2 (35 
Cycles) 
95°C for 30 secs 
55°C for 30 secs 
72° for 30 secs 
 
Final 
Extension 
Stage 3 (1 Cycle) 72°C for 5 mins 
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For any RT-PCR reaction, 5 ng/µl concentration of INS1 cDNA was used (Table 
2.3). The reaction volume was 20 µl and a thermocycler (Applied Biosystems) 
was used for cDNA amplification.  
 
          Table 2.3: RT- PCR master mix. 
Reagent X1 Reaction 
Dream Taq 2x 1x 
cDNA concentration 5 ng/µl 
Forward Primer 0.3 µM 
Reverse Primer 0.3 µM 
 
  
2.3 Primers Selection, qPCR method validation and data analysis 
 
2.3.1 Designing Primers  
 
Exon-spanning primers were designed using National Centre for Biotechnology 
Information (NCBI) BLAST software (https://www.ncbi.nlm.nih.gov/tools/primer-
blast/). Whilst designing the primers, extra care was taken to avoid primer-dimers, 
hairpin loop formation and they were all designed to anneal at 55°C. 
When designing primers, amplicon size was restricted to be 100 to 170 bp, 
because shorter amplicons are amplified with higher efficiency, but also to keep 
amplicon size at least 100 bp which helped to distinguish it from primer-dimers 
that might form. Other factors that were considered where to maintain GC content 
of 45-60%, a melting temperature (Tm) between 58°C and 62°C, to keep the 
primers’ length not more than 23 bp and to ensure to design primers in a way 
which will facilitate to reduce 3’ complementary to avoid primer-dimer formation. 
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2.3.2 Gene expression analysis by quantitative RT- PCR 
 
The use of fluorescent DNA-binding dyes to detect and quantitate a PCR product 
allows quantitative PCR to be performed in real time. Specifically, designed 
instruments perform both thermal cycling to amplify the target and fluorescence 
detection to monitor PCR product amplification. A SYBR green based reverse 
transcriptase qPCR reactions (qRT-PCR) were performed to validate primers and 
to assess gene expression analysis according to MIQE guidelines (Bustin, 2005). 
The qRT-PCR was performed in duplicate using PrimePro48 (TECHNE) and the 
thermal profile is shown in Table 2.4.  
 
At the early stage of PCR cycle very little amount of florescence is generated 
which is considered as noise. As the fluorescence approaches the optical 
detection level, the exponential phase, which is the region where the Cq is 
determined. Cq is the phase where the fluorescence signal crosses the detection 
threshold level and is used for quantification.  The fluorescent dye binds to the 
double stranded DNA and the fluorescence is directly proportional to the DNA 
concentration. Once the reaction components begin to be consumed, the reaction 
reaches the plateau stage. The higher the initial amount of sample DNA the lower 
the Cq values as the product is detected soon. The principal of this method is 
based on fluorescent chemistries, an optical system that can capture the emitted 
fluorescence at every PCR cycle, and the software which is able to quantify the 
PCR amplified product. 
         Table 2.4: Thermal Profile of qRT-PCR reaction. 
Set up the 
thermal 
profile 
Cycling 
Temperature 
(°C) 
    Cycling Time  
Denaturation and 
Polymerase 
activation 
95 10 mins 
PCR cycling 95 15 seconds 
56 30 seconds 
72 30 seconds 
Melt curve 95 15 seconds 
55 15 seconds 
95 15 seconds 
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A melt curve analysis was carried out at the end of the qPCR reaction which 
assess the primers’ quality and specificity. PCR products were also analysed by 
agarose gel electrophoresis during validation to confirm the presence of a single 
product.  Primer efficiencies were determined for all primer pairs. 
To determine the primer efficiency, a standard curve approach was used where 
a serial dilution (10-fold dilution) of cDNA template of known concentration (5 
ng/ul) was used to create a four/three-point standard curve. A number of rat 
housekeeping genes (TATA Biocentre) for example, Tyrosine 3//tryptophan 5-
monooxygenase activation protein (Ywhaz) and peptitylprolyl isomerase A (ppia) 
were also tested. 
Amplification efficiency, E, is calculated from the slope of the standard curve 
using the following formula: 
E=10-1/slope  
 % efficiency was determined by using the formula below: 
%Efficiency = (E-1) x 100%  
Solutions/dilutions for calibration curves were made on the day of analysis and 
then discarded.   
 
2.3.3 Data analysis by relative quantification method 
 
Messenger RNA concentrations were measured of target genes relative to a 
reference gene. In the relative quantification method, one sample is usually 
chosen as the calibrator or control and the expression of the target gene in all 
other samples is expressed as an increase or decrease relative to the control or 
calibrator. In our experiment, GLT treated INS1 cells are test samples which 
calibrated against Ppia in comparison to untreated samples or controls. The 
results (RQ) obtained were expressed as the fold change and the relative amount 
is known as the ‘fold difference’. Relative gene expression was determined using 
the ΔΔCq method (Livak et al, 2001). 
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The fold change relative to reference gene was calculated as follows: 
ΔCq = Cq target gene – Cq reference gene 
- ΔΔCq = ΔCq sample- ΔCq of control 1 
Fold changes to control 1 =2- ΔΔCq  
 
2.4 Microarray analysis 
 
Hybridisation using Affymetrix rat Clariom D arrays (see Figure 2.1 below for chip 
characteristics) was performed at the Genomics Centre, King’s College London. 
Two control- and two GLT-treated samples were analysed (1 control- and 1 GLT-
treated samples from two independent experiments). Analysis was performed 
using the Transcriptome Analysis Console (TAC) 4.0.1 software (ThermoFisher 
Scientific) to analyse and visualise global expression patterns of genes, exons, 
pathways and alternative splicing events. CEL files were provided by the 
Genomics facility, and SST-RMA normalisation was performed in order to 
overcome the historical problem that array data tends to underestimate fold 
changes compared to RT-PCR. Both gene level and exon level analysis were 
performed but focused primarily on the exon analysis. 
 
To identify enriched pathways and functions of the differentially expressed genes 
PANTHER gene list analysis (version 13.1), a large-scale gene function analysis 
was used. We uploaded differentially expressed genes from our exon array 
analysis (Gene+ exon) and got functional classification with gene ontology (GO) 
which allowed us the identification of molecular functions, biological process and 
cellular components among that list of genes provided. The following link was 
used: http: //www.pantherdb.org/data/, for the identification of enriched pathways. 
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Figure 2.1: Characteristics of Affymetrix rat Clariom D arrays. Clariom D solution is 
a GeneChipTM for the next generation transcriptome level providing tools or instrument 
system, providing view of the transcriptome for a faster path to biomarker discovery, 
generate robust expression profiles from total RNA or cells. The chips confidently detect 
genes, exons and alternative splicing events that give rise to coding and long non-coding 
isoforms. In array specifications, numbers are representative of annotations and 
antigenomic background control contains the antigenomic background probes that can 
be used to estimate background expression level. Specification information is collected 
from the data sheet provided on Thermo Fisher Scientific website. 
 
2.5 Gel purification of RT-PCR products for Sanger sequencing 
 
To purify a specific RT-PCR product (e.g. where there were multiple variants 
giving different molecular weight PCR products), and to remove residual 
dNTP/primers, the QIAquick gel purification method was used.  
Gel purification was carried out as the following procedure, using transilluminator 
and with proper UV protection, especially for eyes, DNA fragments were cut from 
the gel and collected in an empty pre-weighed Eppendorf tube. After weighing 
out the gel, three volumes of buffer QG added to one volume gel (100 mg gel = 
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100 µl). The maximum amount of gel per spin column is 400 mg. The gel was 
dissolved by vortex and with the help of temperature (50°C).  A yellow colour was 
the indication of gel slice has dissolved completely. One gel volume of 
isopropanol was added to the sample and placed the sample in a QIAquick spin 
column on a two ml collection tube. To bind DNA, the sample applied to the 
column and centrifuged for 1 minute at 12,000 rpm. The flow-through was 
discarded. At this stage DNA was bound to silica-gel membrane which was then 
thoroughly washed with the ethanol containing PE buffer to remove any 
remaining contaminants and centrifuged for 1 minute at 12,000 rpm, the flow 
through was discarded. Fifty ml of Buffer EB (low concentration of Tris buffer) 
was added to the centre of the column and centrifuged at 12,000 rpm for 1 min 
and collected the yield in a sterile collection tube. DNA quantity and quality were 
then assessed by Nanovue spectrophotometer as described above (section 
2.2.1). 
 
2.5.1 Sanger sequencing and analysis 
 
The purified DNA bands were sent to Beckman Coulter Genomics (GENEWIZ) 
for Sanger sequencing using both forward and reverse primers (as used for RT-
PCR amplification). To analyse gene sequence, it was determined: 
• The composite sequence from the forward and reverse reactions 
• Nucleotide blast search to determine sequence identity 
• The location of specific exons in the sequence 
 
FinchTV 1.4 was used to examine the sequence chromatograms and perform 
a quality check. For reverse primer sequences, an online reverse 
complementation tool was used (‘reverse-complement.com’). Alignment of 
the forward and reverse sequences, or against database sequences, was 
done using the pairwise alignment software Clustalo online. In many cases 
clustalo was not able to account for gaps due to missing exons, and exon 
identification was performed in a semi-manual fashion by aligning one exon 
at a time. 
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2.5.2 Database 
 
The database programmes used for sequence analysis were as followed: 
 
• To open DNA chromatogram files, analyse and manipulate the data from 
Sanger DNA sequencing, the desktop application tool Softpedia was used 
by the following link: http://www.softpedia.com/get/Science-
CAD/FinchTV.shtml  
• To perform BLAST searches, the programme ‘NCBI Blast Toolkit’ was 
used which compares nucleotide sequence to sequence database and 
calculate the statistical significance of matches as well as to help identify 
members of gene families the weblink was used are as follows: 
https://blast.ncbi.nlm.nih.gov/Blast.cgi  
• For multiple sequence alignment, the program ‘Clustao’ was used and the 
link is: https://www.ebi.ac.uk/Tools/msa/clustalo/  
 
2.6 Statistical analysis 
 
Microsoft Excel 2016 spreadsheet was used to calculate mean, fold change, 
standard deviation and standard error of the mean. Two sample t-tests or paired 
t-tests were used to calculate statistical significance. A p value ≤ 0.05 was 
considered significant.  
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Chapter 3 - The Effect of Glucolipotoxic Conditions on β Cell 
Viability 
 
In order to mimic the metabolic conditions that exist in many people with type 2 
diabetes and evaluate the effect on the regulation of splicing in pancreatic β cells, 
we first established and validated an in vitro model of β cell glucolipotoxicity, 
based on published protocols (Bagnati et al, 2016).  To study glucolipotoxicity on 
the pancreatic β cell, we used rat insulinoma cells (INS1), which are pancreatic β 
cells immortalised by radiation (Asfari et al, 1992). 
 
3.1 Validation of INS1 β cell growth characteristics  
 
Understanding cell seeding variation and its effects on proliferation is important 
for controlling assay variability. We therefore performed initial experiments to 
validate growth and seeding densities using the IncuCyte live cell imaging system 
(Method section 2.1.9). 
 
INS1 β cells were plated at a density of 30,000 cells/well in 96 well plates in 
complete (10% FBS) media, and 24 hours growth was monitored as described in 
Methods section 2.1.6. As shown in Figure 1.1A, the Incucyte parameters chosen 
correctly identify cell area at both low confluency (2 hrs) and high confluency (24 
hrs).  Cell growth was seen to increase over time (Figure 1.1B), demonstrating 
the expected pattern of β cell growth including lag phase and exponential cell 
growth.  Due to the short timeframe, the plateau phase was not reached in this 
experiment. However, the cells appeared to be healthy and exhibited the 
expected growth pattern, validating the growth of INS1 cells in my hands. 
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A) 
 
B) 
 
 
Figure 3.1: Validation of β cell growth characteristics under normal conditions. A) 
Representative phase IncuCyte images of INS1 cells showing confluence mask correctly 
quantifies cell area at both low and high cell density. B) Graph shows mean cell area +/- 
SEM, n=3 technical replicates from a single validation experiment.  
 
3.2 Validation of INS1 cell growth in the presence of BSA supplementation 
 
The in vitro glucolipotoxicity protocol used in later experiments is based on the 
method reported by Oliveira et al, 2015, which involves the use of free fatty acids 
bound to albumin to resolve the problem of low free fatty acid solubility.  Since 
supplementation with two percent bovine serum albumin will be used for fatty acid 
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conjugation in later experiments, the effect of this supplementation on β cell 
growth was therefore first validated.  
INS1 cells were plated as above then, after allowing the cells to adhere for 24 
hours, the media was replaced with fresh media supplemented with or without 
two percent BSA. Both serum free and complete media was used for this 
experiment. INS1 cell growth was monitored by live cell imaging for 35 hours.  
 
FIGURE 3.2: β cell growth under conditions of BSA supplementation.  INS1 cells 
were cultured in either complete or serum free media (SF) and supplemented with 
with/without two percent BSA. Cells were incubated without 2% BSA in both complete 
and serum free media served as ‘control’ in this experiment in order to observe the effect 
of extra 2% BSA on INS1 cell growth. Graph shows mean +/- SEM (n=6 technical 
replicates from a single experiment). A polynomial trending curve has drawn for 2% BSA 
complete (poly. (Complete (2%BSA)) with a R2 value is 0.925 which indicates a good fit 
of the line to data means less fluctuation of data with a smooth curve. 
 
 
Both cell confluency and cell area were used to evaluate the growth pattern of 
INS1 cells in two percent BSA conditions and gave similar results.  As shown in 
Figure 3.2, the addition of two percent BSA had no effect on cell growth in 
complete media, with both control and BSA treated cells demonstrating similar 
lag, growth and plateau stages.  In serum free conditions, a decrease in cell 
number was observed at around 24 hours, presumably due to the lack of 
essential nutrients and growth factors provided by serum.  The presence of two 
percent BSA prevented this decrease, and cell growth in the presence of BSA 
and absence of serum was similar to growth in complete media. Subsequent 
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experiments will use complete media, and the presence of BSA supplementation 
does not affect cell growth under these conditions.   
 
3.3 The Effect of glucolipotoxic treatment on β cell growth 
 
To validate GLT treatment, INS1 cells were treated with GLT media (Method 
section 2.1.7) to see the effect of a high concentration of sugar and fatty acids on 
β cell growth. 
 
For GLT treatment, INS1 cells were incubated for five days in the presence of 
200 µM palmitic acid, 200 µM oleic acid and 27mM glucose (Bagnati et al, 2016). 
Both serum free and complete media conditions were used initially to assess the 
effect of GLT treatment on β cell growth. The control media contained the same 
BSA/ethanol concentration but lacked free fatty acids (see methods for further 
details). Standard RPMI media contains 11 mM glucose which is euglycemic in 
human. The normal blood sugar level in human is between 4.0 to 5.5 mmol/L 
which represents a species difference between rodent and human. However, we 
supplemented the media with an additional 16 mM glucose (Bagnati et al, 2016) 
to create glucose toxicity in INS1 cells. INS1 cell growth was then monitored using 
the IncuCyte for five days following GLT or control treatment and images were 
taken each two-hour interval. 
 
As shown in Figure 3.3, in serum-free conditions, GLT treatment initially offers 
some growth advantage, perhaps due to the high glucose levels, since glucose 
is known to induce β cell proliferation (Stamateris et al, 2016).  However, after 72 
hours, cell growth under GLT conditions was decreased dramatically in 
comparison to control and from this time point cells start to change their 
morphology, assuming a rounded shape and reducing adherence to the plate. A 
two-sample independent t-test was carried out as a statistical end point analysis 
(120 hours) and p=0.2 value in the Kolmogorov-Smirnov test (K-S) confirmed the 
normal data distribution which is prerequisite to perform a t-test. The end point, 
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analysis has shown that a significant decrease (p=0.0006) in cell number is 
observed in GLT treated cells due to the toxicity experienced by the cells. 
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FIGURE 3.3: A) The effect of GLT treatment on cell growth (serum free 
conditions). The graph shows mean cell area per square meter +/- SEM, 
(n=6).  Two independent experiments have been carried out where technical 
replicates were six. B) Images (serum free) on control and GLT conditions 
(CON vs GLT). 
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Similar to serum free conditions, three growth stages (Figure 3.4) are observed 
in complete conditions, for example at the growth stage (up to 18 hours), initial 
plateau (from 18 to 72 hours) and toxicity stage (after 72 hours). As we discussed 
earlier, initial growth advantage is observed in the growth stage and the dramatic 
fall in cell area is observed in cells with high levels of sugar and fatty acids after 
72 hours. An end point growth analysis at 120 hours shows that the average cell 
area significantly decreases (p=0.002; n=6; two sample t-test) in GLT treated 
cells in comparison to controls. Data was checked for normality and a p=0.2 in 
the Kolmogorov-Smirnov test confirmed normal data distribution. Similar results 
were obtained in 2/3 experiments (data not shown). 
 
3.4 Discussion 
 
In conclusion, GLT treatment caused a dramatic decrease in cell number both in 
serum free and complete media conditions. Although the concentration of free 
fatty acids (free rather than albumin conjugated) is easier to quantify in serum 
free conditions; it is more physiological to perform the growth curve in the 
presence of serum, and complete media conditions were used for all experiments 
going forwards. In future, the effect of high glucose and free fatty acids on INS1 
cells can be assessed on caspase activation. 
To demonstrate the toxicity effect of GLT on β cell growth, apoptosis should be 
monitored with progressive activation of caspase 3 and this can be a part of our 
future analysis. 
To study glucolipotoxicity on the pancreatic β cell, we used the rat INS1 β cell 
line.  However, we could have used at least another rat beta cell line e.g. RIN, 
MIN, HIT etc to see if similar changes occur in our study. It would be very useful 
to examine the results in human beta cell line EndoC-βH1 which can also be a 
part of future study. 
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Chapter 4 - The effect of GLT treatment on the expression of 
alternative splicing (AS) regulatory genes 
 
The aim of this part of the study was to determine the effects of high glucose and 
fatty acid conditions on β cell expression of a panel of genes known to regulate 
alternative splicing.   
 
4.1 Selection of a Panel of Genes that Regulate Alternative Splicing 
 
Based on a review of the literature, we selected a panel of eleven trans-acting 
splicing factors, including serine/arginine rich (SR) proteins, heterogenous 
nuclear ribonucleoproteins (hnRNPs), and a set of neuron-specific splicing 
regulatory proteins (RBPs) that are known to be expressed in β cells e.g. Elav-
like family member proteins, Rbfox1 & 2 and Nova1 & 2 family. The genes chosen 
are not the core components of the splicing machinery, rather they are involved 
in the regulation of alternative splicing. A full list of the genes selected and a brief 
description of their role in AS is given in Table 4.5. Primers were then designed 
(Method 2.3.1) to analyse the expression of these genes by qRT-PCR, and for 
another set of genes to be analysed for suitability as housekeeping genes. The 
selected AS genes and corresponding Gene bank accession numbers and the 
sequences of the primers designed, are listed in Table 4.6. Exon-spanning 
primers were designed using NCBI Blast software and validated for SYBR green 
qRT-PCR using PrimePro-48 (Techne) real time PCR system.  
  
4.2 GLT treatment and validation of RNA integrity 
 
The titration of the growth curve, as discussed in chapter 3.3, helped us to choose 
a suitable time-point during the plateau phase, since β cells are not highly 
replicative in the adult pancreas, but before the initiation of β cell loss since 
secondary changes are likely to occur during the process of cell death. The time-
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point chosen was 46-hour. Four independent experiments were performed, each 
with n=3 technical replicates. Growth was monitored at regular 8-hour intervals 
under an inverted microscope. RNA was then extracted, and the integrity and 
quantity assessed using an Agilent Bioanalyzer or Nanovue spectrophotometer 
(Method section 2.2.1). For selective samples, RNA integrity and quality were 
assessed using Agilent Bioanalyzer (Figure 4.1) which was performed at the 
Genomics Centre, Kings College London. 
 
Table 4.5: The panel of AS regulatory genes selected for analysis and 
function of the protein product is summarised based on information 
obtained from the NCBI database and different publications. 
 
Name of Splicing 
Regulator/Factor 
Gene 
symbol 
Function 
Serine and 
Arginine rich 
splicing factor 1 
Srsf1 Required in splice site recognition, ATP-
dependent interactions of both U1 and U2 
snRNP with pre-mRNA plays a role in 
preventing exon skipping ensuring the accuracy 
of splicing and regulating AS (Claudia et al, 
2010). Acts as an adaptor protein to recruit 
signalling molecules during tumorigenesis, 
overexpressed in some cancers and regulates 
alternative splicing of many cancers regulated 
genes (Claudia et al, 2010). 
Serine and 
Arginine rich 
splicing factor 3 
Srsf3 Shuttles between nucleus and cytoplasm 
(shuttling SR proteins), (Jeong et al, 2017). 
Involved in RNA processing in relation with 
cellular proliferation and/or maturation (Claudia 
et al, 2010). 
Serine and 
Arginine rich 
splicing factor 5 
Srsf5 Involved in constitutive splicing, can modulate 
the selection of AS (Claudia et al, 2010). 
Serine and 
Arginine rich 
splicing factor 6 
Srsf6 Promotes expression of isoforms of 
extracellular matrix protein tenascin C, Dvinge 
et al, 2016. Involved in constitutive splicing, can 
modulate the AS sites. Repress the splicing of 
MAPT/Tau exon 10. RNA binding (Claudia et al, 
2010). 
Serine and 
Arginine rich 
splicing factor 10 
Srsf10 Involved in constitutive and regulated RNA 
splicing (Claudia et al, 2010). 
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Heterogenous 
nuclear 
ribonucleoprotein 
F 
Hnrnpf Belongs to hnRNP family, highly conserved 
from nematode to mammals and play a role in 
pre-mRNA maturation. Their function is to bind 
the exonic splicing silencer (ESS) to exclude 
trans-acting factors such as SR proteins from 
cis-acting elements (Wang et al, 2014). A pre-
mRNA splicing factor that may be involved in 
the coordination of transcription and splicing 
(RGD, Feb 2006). 
RNA binding fox-1 
homolog 1 
Rbfox1 The Fox-1 family of RNA-binding proteins is 
evolutionarily conserved and regulates tissue-
specific alternative splicing in metazoa. Fox-1 
recognizes a (U)GCAUG stretch in regulated 
exons or in flanking introns. Several 
alternatively spliced transcript variants 
encoding different isoforms have been found for 
this gene. [provided by RefSeq, Nov 2011]. 
Rbfox1 regulates β cell function of insulin 
secretory capacity without affecting the cells 
viability (Mateu et al, 2017). 
RNA binding fox-1 
homolog 2 
Rbfox2 Rbfox2 regulates β cell function affecting the 
insulin secretory capacity but without affecting 
the cells viability (Mateu et al, 2017). This gene 
encodes an RNA binding protein that is thought 
to be a key regulator of alternative exon splicing 
in the nervous system and other cell types 
(Jiang, et al, 2008). The protein binds to a 
conserved UGCAUG element found 
downstream of many alternatively spliced exons 
and promotes inclusion of the alternative exon 
in mature transcripts. Multiple transcript variants 
encoding different isoforms have been found for 
this gene. [provided by RefSeq, Jul 2008] 
NOVA alternative 
splicing regulator 
1 
Nova1  Required for β cell survival, and their depletion 
leads to activation of the intrinsic pathway of 
apoptosis. (Mateu et al, 2017). Alternatively, 
spliced transcripts encoding distinct isoforms 
have been described. [provided by RefSeq, Jul 
2008] 
NOVA alternative 
splicing regulator 
1 
Nova2 Required for β cell survival, and their depletion 
leads to activation of the intrinsic pathway of 
apoptosis. (Mateu et al, 2017). 
Polypyrimidine 
tract binding 
protein 1 
Ptbp1 Belongs to heterogenous ribonucleoprotein 
family (hnRNPs). The hnRNPs are RNA-binding 
proteins and they complex with heterogeneous 
nuclear RNA (hnRNA) (Ghetti, et al, 1990). 
They are present in the nucleus, associated with 
pre-mRNA processing and some of them shuttle 
between nucleus and cytoplasm. The hnRNP 
proteins have distinct nucleic acid binding 
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properties (Ghetti et al, 1990). This protein 
binds to the intronic polypyrimidine tracts that is 
required for pre-mRNA splicing and acts via the 
protein degradation ubiquitin-proteasome 
pathway. It may also promote the binding of U2 
snRNP to pre-mRNAs [ RefSeq, Jul 
2008].  Involved in the negative regulation of 
alternative splicing [RGD, Feb 2006]. 
ELAV like RNA 
binding protein 1 
(HuR) 
Elavl1 This gene belongs to the ELAV family of RNA 
binding proteins predominantly localized within 
the nucleus. As a trans-acting factor, it can bind 
AU-rich element (AREs) of 3’ untranslated 
region. AREs signal degradation of mRNAs to 
regulate gene expression, thus by binding 
AREs, the ELAVL family of proteins play a role 
in stabilizing ARE-containing mRNAs and/or 
protein translation. (RefSeq, Sep 2012 and 
Wang et al, 2013). The role of Elavl1 in β cells 
is not known, but it has been shown previously 
that siRNA knockdown of the related family 
member, Elavl4, increased β cells apoptosis 
(Mateu et al, 2017), suggesting that this family 
genes can regulate β cell survival.   
 
ELAV like RNA 
binding protein 4 
Elavl4 siRNA knockdown of the ELAVL family 
member, Elavl4, increases of β cells apoptosis, 
suggesting that this family of genes can regulate 
β cell survival. It functions in mRNA turnover 
and function including AS, stability and 
translation. (Mateu et al, 2017) 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
Table 4.6: List of genes with their nucleotide sequences of primers utilized 
in this study. 
Gene 
name 
Database 
accession 
number 
Forward primers’ 
sequence (5’-3’) 
Reverse primers’ (5’-3’) Expect
ed 
produ
ct size 
Hnrnp
f 
NM_001037
285.1 
CCTTCCTCCCGTGGAA
AACTTG 
GCATCATGGACACTTGA
CAGG 
133 
Ptbp1 NM_001271
057.1 
AAGCTCACCAGTCTCA
ACGTC 
TACGGAGAGGCTGACAT
TATGC 
149 
Srsf1 NM_001109
552.2 
CCGCGAGACGCGGAA
GAT 
CACTCTGTTTTCAGACC
GCCT 
180 
Sfsf3 NM_001047
907.3 
CACTCCGAAGTGTGTG
GGTT 
GGCAGCCACATAGTGTT
CTTC 
120 
Srsf5 NM_001195
505.1 
AGCGCAGTTGATTGAG
GAAAC 
CTGATCCGTCCGTAACC
CTTG 
127 
Srsf6 NM_001014
185.2 
AAAGTCGCTCGCGATC
TAGG 
AATGTGAATGGGAACCC
CGA 
120 
Srsf1
0 
NM_001025
738.1 
CTACACTCGACGTCCA
AGAGG 
TGATTTGGTGTCTTCCGA
TCCC 
150 
Rbfox
1 
NM_001106
974.2 
GCGGTGTTGTTTACCA
GGAT 
GTCGGCAGCATAAACTC
GTC 
134 
Rbfox
2 
NM_001079
895.1 
GTGCTGACCTCTATGG
TGGA 
TGTGTACACCCTGCCGT
AAC 
122 
Nova2 XM_008759
097.1 
CAGGATTGAGTGACGG
CTGAG 
ACAGATATCACATAGAC
CTGGACC 
132 
Elavl4 NM_001077
651.2 
CTGTAAGAAGGGAATG
TCGGCT 
ATGTCGGTCCATTTGAC
ACC 
150 
Gapd
h 
NM_017008.
4  
AGTGCCAGCCTCGTCT
CATA 
ATGAAGGGGTCGTTGAT
GGC 
133 
Dp5 NM_057130.
4 
GATTGTGCCAGAGCTT
CACA 
GATTGTGCCAGAGCTTC
ACA 
125 
Atf3 NM_012912.
2 
GCTGGAGTCAGTCACC
ATCA 
ACACTTGGCAGCAGCAA
TTT 
127 
Elavl1 NM_001108
848.1 
TGACAAACGGTCTGAA
GCAG 
CCTGAATCTCTGTGCCT
GGT 
196 
Nova1 NM_001100
541.1 
GGAGCAGTCAGGGGCT
TGGG 
TGAGACAGCTGCCACTC
TGTGGA 
161 
Gsn NM_001004
080.1 
CTTTGTTTGGAAAGGCA
AGC 
GGGGTACTGCATCTTGG
AGA 
221 
Cacna
1c 
NM_012517.
2 
AGTGATCCCTGGAATG
TTTTTG 
AGGACTTGATGAAGGTC
CACAG 
210 
Insr NM_017071.
2 
TGCACAACGTGGTTTTT
GTT 
TCTCTTCTGGGGAGTCC
TGA 
291 
Tubb5 NM_173102.
2 
GTGATAAGCGATGAAC
ACGGC 
GGGACATACTTGCCACC
TGTA 
116 
B2m NM_012512.
2 
TCGTGCTTGCCATTCA
GAAAAC 
GTGGAACTGAGACACGT
AGCA 
100 
Ppia NM_017101.
1 
CAGACGCCGCTGTCTC
TTTTC 
TGCAAACAGCTCGAAGC
AGAC 
115 
Ywha
z 
NM_013011.
3 
ACAACTTGACATTGTGG
ACATCG 
TGGGACAGCATGGATGA
CAAA 
 
143 
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FIGURE 4.1: Analysis of RNA integrity and quality by Agilent Bioanalyzer. All 
the samples were assigned a RIN number 10, indicative of high quality RNA. A) The 
Electropherogram and gel images of RNA 6000 Nano Ladder and B) Total RNA 
sample had shown two distinct, 18s and 28s, ribosomal peaks and relatively flat 
baseline between 5s and 18s ribosomal peaks which confirms the RNA integrity and 
a successful run of the Bio analyser experiment.  
A) 
B) 
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4.3 Validation of primer specificity by RT-PCR. 
 
Expression of a single PCR product of the expected size in INS1 cells using the 
gene-specific primers was initially validated by RT-PCR. Amplification was 
performed as indicated in Method (section 2.2.3), and products were loaded onto 
2% agarose. Negative controls were also performed to test for genomic and other 
contamination. A specific product of the expected size was seen for all selected 
genes in Table 6, except for Rbfox1 and Srsf1 as shown in Figure 4.2. Rbfox1 
and Srsf1 genes were not detectable in INS1 cells using the current primers 
(Table 6) and were not analysed further. Agarose gel analysis (Figure 4.2) has 
shown that all genes were lacking in primer dimer formation which is important 
for subsequent qRT-PCR experiments using SYBR green. 
Table 6 shows all predicted amplicon sizes. No PCR amplifications in negative 
controls in our validation reaction confirmed the absence of contamination, in 
particular the NRT which tests for genomic contamination. NTCs detect PCR 
contamination and can also distinguish unintended amplification (Figure 4.2). 
  
4.4 Evaluation using melt curve analysis 
 
It must be ensured that PCR conditions yield only specific product which we 
verified by a melt curve analysis (Figure 4.3). Thermal melt curves are formed by 
placing all double-stranded DNA products at lower temperatures, which is around 
60°C, and allowing a slow increase in temperature to denaturing level which is 
around 95°C. The length of product and sequence affects melting temperatures; 
therefore, the melt curve is used to characterise amplicon homogeneity. Non-
specific amplification is identified by wide peaks in the melt curve or peaks with 
unexpected Tm values. In conclusion, via a melt curve analysis, we have shown 
the specificity of primers in a qRT-PCR (Figure 4.3). 
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Figure 4.2: Validation of a panel of alternative splicing regulators and endogenous 
control genes by reverse transcriptase PCR. Images of agarose (2%) gels showing 
the PCR product specificity of A) positive control Gapdh and splicing factor Rbfox2 along 
with reverse transcriptase minus (RT-) negative controls (NRT) and dH2O. No 
amplifications were observed in negative controls. Expected PCR products were 
measured by comparing the amplicons with 100bp DNA ladder. No primer dimers 
formation was observed on gel. B) Splicing factor Rbfox1 shown very faint PCR amplicon 
(around 35-36 Cq value in qPCR), but Ptbp1 showing clear specific product. No 
amplification was observed in negative controls. C)  Splicing factors Srsf1 shows very low 
amplification (Cq value was around 36-37 in qPCR). However, SR primers: Srsf3 and 
Srsf5 have shown specific single PCR product with clean negative controls. Similarly, D) 
Splicing factor Elavl1, E) SR primers Srsf6 and Srsf10; F) rat endogenous control genes 
Tubb5, Ywhaz, Ppia and M2b and G) Elavl4, Ptbp1, Nova2, stress primers Atf3, Dp5 and 
Rbfox2 primers amplification showing single specific product. 
G) 
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Ptbp1 
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Green peak corresponds to Ppia and blue to 
Ywhaz. 
Green peak corresponds to Gapdh and blue to 
Srsf10. 
Figure 4.3: Melt curve analysis of all primers used in qPCR experiments. 
A single peak for each primer represents primers specificity; the presence of 
wider peaks or more than one peak is the indication of formation of primers 
dimers. 
Dp5 
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4.4 Validation of primer efficiency and specificity using qRT-PCR 
 
Further validation of primers’ specificity and efficiency was performed using 
SYBR green based qRT-PCR before embarking on further gene expression 
analysis. To optimise the PCR amplification, primers efficiency is essential for 
accurate and reproducible quantification. Therefore, we validated primer 
efficiency for both target genes and a panel of reference genes. Primers Atf3 and 
Dp5 have not been fully validated as those primers’ sequences were obtained 
from Oliveira et al, 2015. 
 
4.4.1 Primer efficiency  
 
To determine the primer efficiency, serial dilution of the cDNA template was 
performed and Cq values were plotted against the log dilution. Amplification 
efficiency was calculated as indicated in the method section 2.3.2. Amplification 
of each sample was conducted in duplicate. 
Figure 4.4 has shown that linear standard curves for all our selected panel of 
genes and also for endogenous control genes, Ppia and Ywhaz, with R2, the 
coefficient of determination, values >0.99 (Table 4.7). The assay reflected 
primers high amplification efficiency with a range of 90-110% (Techne manual), 
A 100% efficiency indicates that the amount of product doubles with each cycle 
and a range outside that acceptable range is an indication of a problem with PCR 
reaction set up or with the template.  
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Figure 4.4: Generation of a standard curve from serial dilution (10-fold) of 
nucleic acid template of known concentration. Standard curves with the Cq mean 
plotted against the log of the starting quantity of template for each dilution. The 
equations for the regression line and R2 values are shown on graphs.  
59 
 
A summary of the primers’ efficiency performance is shown in Table 4.7. 
Table 4.7: A summary of Primers’ Efficiency Performance. 
 
Gene 
name 
Single 
PCR 
product 
with no 
primer 
dimer 
Melt 
curve 
analysis 
%Efficiency 
Accepted 
range (90-
110; 
Techne 
Mannual) 
 
R2 value Clean 
negative 
controls 
Passed 
all 
validation 
Gapdh Yes Single 
peak 
103 0.99 Yes Yes 
Rbfox2 
Yes Single 
peak 
92 0.99 Yes Yes 
Nova2 
Yes Single 
peak 
94 0.99 Yes Yes 
Elavl4 
Yes Single 
peak 
104 0.99 Yes Yes 
Hnrnpf 
Yes Single 
peak 
106 0.99 Yes Yes 
Ptbp1 
Yes Single 
peak 
98 0.99 Yes Yes 
Srsf3 
Yes Single 
peak 
100 0.99 Yes Yes 
Srsf5 
Yes Single 
peak 
102 0.99 Yes Yes 
Srsf6 
Yes Single 
peak 
95 0.99 Yes Yes 
Srsf10 
Yes Single 
peak 
104 0.99 Yes Yes 
Elavl1 
Yes Single 
peak 
102 0.99 Yes Yes 
Ywhaz 
Yes Single 
peak 
103 0.99 Yes Yes 
Ppia 
Yes Single 
peak 
102 0.99 Yes Yes 
Rbfox1 
No Not 
applicable 
Not 
applicable 
Not 
applicable 
Yes No 
Srsf1 
No Not 
applicable 
Not 
applicable 
Not 
applicable 
Yes No 
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4.5 Validation of housekeeping gene stability under GLT conditions 
 
To compensate for slight variation in template amount qRT-PCR, we need to 
normalise expression to a housekeeping gene and that expression of the 
housekeeping gene must be constant across different treatment conditions for 
this to be valid. Therefore, we examined the stability of the initial reference gene, 
Gapdh. To do that, four independent experiments were performed in which INS1 
cells were treated with high sugar and high fatty acids (GLT treatment) or control 
as described in method section 2.1.7. Total RNA was extracted (section 2.2.1) 
and cDNA was synthesised and amplified by qRT-PCR using Gapdh gene. A 
statistical data analysis by K-S (Kolmogorov-Smirnov analysis) test ensured a 
normal data distribution by a p value >0.05 which were analysed by SPSS (v.24). 
We collected our relative analysis data, ∆∆Cq values expressed as fold change 
compare to control 1 (Livak et al, 2001), of Gapdh control vs. GLT for all four 
experiments and allowed them in statistical analysis of two samples independent 
t-test (Mean +/- SEM; Figure 4.5) each with three technical replicates. 
 
As shown in Figure 4.5, our data showed decreased expression of Gapdh mRNA 
in the presence of high glucose and high fatty acids conditions decreased in ( 
Exp A, p<0.09; Exp B, p<0.06 and in Exp D, p<0.1) and a significant increased  
expression was observed in Exp C, p>0.004. Despite Gapdh being a commonly 
used reference gene for GLT studies (Mateu et al, 2016; Bagnati et al, 2016), in 
our hands Gapdh expression is therefore unstable under GLT conditions and 
should not be used. In such a situation, we decided to select a further set of 
housekeeping genes (Table 6) from the list provided by ‘TATAA Biocentre’ on 
their web page, designed their exon-exon spanning primers and validated them 
as described above.  
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FIGURE 4.5: Stabilisation of Gapdh as a housekeeping gene on Glucolipotoxic 
Conditions. qRT-PCR analysis of Gapdh expression under GLT and control conditions. 
Data represents 4 independent experiments. Data shows Cq mean +/-SEM. Statistical 
analysis using two sample independent t-test.  A p value <0.05 indicates statistical 
significance. 
 
Among the four housekeeping genes (Tubb5, M2b, Ywhaz and Ppia; Table 6), 
Ppia and Ywhaz were randomly selected for further validation on GLT conditions. 
Using the same cDNA samples prepared from 4 independent experiments, as 
described above in section 4, a qRT-PCR was performed using primers specific 
for those genes (Ywhaz and Ppia) to determine Cq values in both control and 
treatment conditions in all four experiments. A two-tailed independent two sample 
t-test was carried out to analyse the data. Data analysis clearly guided us by 
concluding that among the three reference genes, Ppia (p=0.7) is highly stable 
under GLT conditions while Gapdh (p=0.2) and Ywhaz (p=0.2) were the least 
stable (Figure 4.6). 
 
In conclusion, we have shown that Ppia expression is stable under GLT 
conditions, and conversely that Gapdh should not be used as a qRT-PCR 
housekeeping gene in this type of study. 
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Figure 4.6: Endogenous housekeeping gene Ppia is the most conserved on GLT 
conditions. Graph shows Cq mean +/- SEM, n=4. Statistical analysis using two tailed 
paired t-test.  
 
4.6 Validation of stress response gene upregulation following GLT 
treatment 
 
In order to validate the response to GLT treatment at the level of gene expression, 
we used published primers to two genes involved in stress responses that are 
known to be upregulated in INS1 cells following GLT treatment (Cunha et al, 2008 
and Oliveira et al, 2015). Glucolipotoxicity induced β cells apoptosis via induction 
of ER stress or activation of mitochondrial pathway of cell death which has 
already been discussed in section 1.4.1. Activation transcription factor 3 mediates 
the ER stress response along with spliced X-box binding protein 1 (XBP1s) and 
C/EBP homologous protein (CHOP), as well as the proapoptotic BCL-2 family 
member death protein 5. We therefore randomly selected Atf3 and Dp5 to 
investigate the stress response on INS1 β cells induced by GLT. 
 
Using the same cDNA samples prepared from 4 independent experiments, as 
described above in section 4.5, expression of the stress response gene Dp5 and 
Atf3 was determined by a qRT-PCR, using Ppia as a reference gene. Normal 
distribution of data was confirmed before any further statistical analysis. As 
shown in Figure 4.7, although no change in Atf3 expression was observed, a 
significant increase in Dp5 expression (p=0.01, n=4) following GLT treatment was 
observed, consistent with previous publications (Oliveira et al, 2015). 
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In conclusion, increased expression of the stress-marker Dp5 mRNA following 
GLT treatment, validated the effectiveness of our GLT treatment.       
 
 
 
 
Figure 4.7: Validation of glucolipotoxicity by induction of stress markers. Data from 
four independent experiments, they were normalised for the expression level of the 
housekeeping gene Ppia and a significant increase (two sample paired t-test) in 
expression of Dp5 mRNA validates the effectiveness of GLT treatment. Graph shows 
mean fold change +/-SEM. 
 
4.7 Expression of alternative splicing regulatory genes following GLT 
treatment 
 
To test the hypothesis that the expression of genes that regulate AS is affected 
by GLT treatment, we used the panel of AS gene primers validated the above 
sections, cDNA synthesized using RNA isolated from the four GLT treatment 
experiments (each with n=3 technical replicates) as described previously (section 
4.5) was used in qRT-PCR reactions with each of the primer pairs, and Ppia was 
used as a reference gene to calculate fold changes using the ∆∆Cq method.  
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As shown in Figure 4.8, the splicing regulator Elavl1 is upregulated in INS1 β cells 
following GLT treatment (p=0.04, n=4, two-tailed paired sample t-test).  
 
No significant changes in the regulation of serine/arginine rich (SR) family genes 
e.g. Srsf3 (p=0.8, n=4), Srsf5 (p=0.5, n=4), Srsf6 (p=0.7, n=4) and Srsf10 (p=0.9, 
n=4.) were observed, suggesting that these trans-activating splice factors are not 
affected by GLT treatment. A slight decrease in Ptbp1 and Hnrnpf expression 
was observed but this did not reach statistical significance (p=0.3, n=4 for both 
genes). Further experiments would be required to determine whether these are 
real decreases or just experimental variation. 
 
 
 
Figure 4.8: Regulation of RBPs, hnRNP and SR family genes following GLT 
treatment. Expression was normalised to Ppia, and relative to a single control value. 
Data represents 3-4 independent experiments, each with 3 technical replicates. Graph 
shows mean fold change +/- SEM. Graph indicates mean fold change relative to a single 
control sample.  A p value <0.05 indicates statistical significance 
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4.8 Discussion 
 
• In this study, we selected and tested 13 splicing regulatory genes under 
GLT conditions based on some published literatures. There are some 
notable omissions that are expressed in β cells for example, some 
negative trans-acting factors hnRNPs (Hnrnpa1 and Hnrnpa2b1) which 
are found to be associated with cancer and ageing (Section 1.5.3), should 
be tested under GLT conditions.  In future, more SFs expression should 
be tested and the Clariom data will be useful in selecting and testing SFs 
in altered metabolic conditions. 
 
• We have shown that reference gene rat Ppia expression is stable under 
GLT conditions, and conversely that Gapdh should not be used as a RT-
qPCR loading control in this type of study. 
 
• These experiments showed that GLT conditions significantly increase 
(p=0.04, n=4) expression of the stress-associated mRNA processing and 
stability gene Elavl1 in β cells. 
 
• The role of Elavl1 in β cells is not known, but it has been shown previously 
that siRNA knockdown of the related family member, Elavl4, increased β 
cell apoptosis (Mateu et al, 2017), suggesting that this family of genes can 
regulate β cell survival. 
 
• Elavl1, also known as HuR, is an RNA binding protein that is known to be 
upregulated in multiple types of cancer (Jun et al, 2013). It has been shown 
to bind near 3’ splice acceptor sites and to regulate alternative splicing, for 
example of the translation regulator Eif4enif1 and the apoptosis receptor 
Fas (Chang et al, 2014). The protein functions of HuR are not clear as no 
target sequences of HuR have not been identified yet (Izquierdo, 2008). 
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In summary, these experiments demonstrate that exposure to high glucose and 
free fatty acid conditions increases expression of the splicing regulator Elavl1 in 
β cells.  This suggests that the metabolic conditions that exist in some people 
with type 2 diabetes may similarly upregulate Elavl1. 
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Chapter 5 - RT-PCR alternative splicing of candidate gene 
 
Variation in TCF7L2 is an important factor determining T2D risk and is known to 
be regulated by alternative splicing (as summarised in introduction section 1.6.1). 
We therefore wished to examine whether GLT treatment and the upregulation of 
Elavl1 were associated with changes in Tcf7l2 isoform expression in β cells. 
 
5.1 Identification of rat Tcf7l2 splice variants analysis and their regulation 
by GLT conditions 
 
5.1.1 Initial analysis of rat Tcf7l2 
 
The human genomic structure of TCF7L2 consists of 17 exons and is abundantly 
expressed in pancreatic islets, adipose tissue, (Osmark et al, 2009). Previous 
research revealed by other groups has revealed tissue-specific splicing pattern 
of this gene and four splice variants expressed in pancreatic islets, (Hansson et 
al, 2010). In β cells, four primary splice variants (see introduction; Figure 1.7) 
were identified in one study (Hansson et al, 2010). However, other studies have 
identified additional variants based on alternative splicing of the same regions (Le 
Bacquer et al, 2011). So far, no splice variants have been reported for rat Tcf7l2 
in the database. We therefore performed an initial comparative analysis of the rat 
and human exon structures to identify in rats, the regions known to be 
alternatively spliced in human β cells. 
 
There are 30 transcripts of the human TCF7L2 gene identified in ENSEMBL, of 
which 21 are predicted to be protein coding. As shown in Figure 5.1 two regions 
that are alternatively spliced in human β cells are exon 4 at the 5’ region, and 
exons 13-16 in the 3’end (Duval et al in Hansson, 2010). The first exon in the rat 
Tcf7l2 gene is not annotated as an exon in the human TCF7L2 sequence.  
Human exons1-3 are also not annotated as exons in the rat sequence, raising 
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the possibility that the 5’ mRNA sequence is distinct in rats and humans. 
However,  the sixth human exon  is homologous with  rat exon 2.  The alignment 
of specific human/rat exons are shown in Appendix Figure 9.4. 
 
Looking at the second alternatively spliced region in the human gene (exons 13-
16), human exon 11 and 12 are homologous to rat exons 7 and 8, respectively, 
human exon 15 is homologous to rat exon 9, and human exon 17 is homologous 
to rat exon 10 (Figure 5.1). However, the alternatively spliced human exons 13, 
14 and 16 are not annotated as exons in the rat sequence. 
 
 
 
Figure 5.1: A comparison of TCF7L2 exon structure between human and rat in 
database. Human exon structure and numbering (see Figure 1.7) has been adapted 
from Hansson et al, 2010. 
 
Based on this analysis, we designed primers to amplify and sequence the rat 
exons 1 to 2 (Region 1) and exons 7 to 10 (Region 2) using NCBI database (Table 
5.8), and look for multiple PCR products as evidence of Tcf7l2 alternative splice 
variants in the rat.  
- Indicates AS region in human islets (+/-
exon4, lack exons 13, 14 and 16 but +/- 
exon15); AS creates truncated proteins. 
- Indicates primary association SNP with 
T2D 
11 9 10 1 2 3 4 5 5+ 6 7 8 12 13 14 15 16 17 
human 
1 2 3 4 5 6 7 8 9 10 
rat 
rs7903146 
Region 1 Region 2 
Human exon structure adapted from Hansson et al, 2010 
Alternatively spliced 
Spliced out 
Constitutive exon 
In human islets: 
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Table 5.8: Nucleotide sequence of primers for Tcf7l2 amplification in region 
1 and region 2 by RT-PCR in rat pancreatic β cells. 
Primer name Database 
accession 
number 
Forward 
primers’ seq 
Reverse 
primers’ seq 
Expect
ed 
produc
t size 
Tcf7l2 1F and 2R NM_00119
1052.1 
ACTCCTTACAAA
AGGTTGGGGA 
TTGCTGTACG
TGATGAGAGG
TG 
109 
Tcf7l2 7F and 
10R 
NM_00119
1052.1 
CTGGTCTGCAC
GGGATAACT 
GCAGCTGCCT
TCACCTTGTA 
190 
 
5.1.2 Analysis of the Tcf7l2 splice pattern in INS1 cell 
 
To analyse the splice pattern in rat INS1 cells, total RNA was extracted and 
reverse transcribed, and RT-PCR was conducted using two pairs of primers listed 
above. Exon 1-2 PCR showing the presence of four amplicons, named as A1-A4; 
low to high molecular weight. In region 2, another four PCR amplicons were 
identified (A5-A8; low to high molecular weight). After sanger sequencing of 
purified PCR products, no splice variants were identified in region 1, the reason 
for which may be that the 5’ mRNA site is distinct in rats as we have discussed in 
above section 5.1.1. In region 2, we successfully identified three novel 
alternatively spliced isoforms, named as B (A5), C (A6) and D (A8), along with 
discovering three new novel exons, namely 8b, 8c and 9b, which are assumed to 
be the primary variants expressed in β cells (Figure 5.2). Predicted PCR amplicon 
was named as A. A schematic presentation summarizing the splice pattern in 
Tcf7l2 has shown in Figure 5.3. A summary of this sequence analysis has shown 
in Table (Appendix 9.9).  
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Figure 5.2: Splice variants analysis of rat Tcf7l2 on pancreatic β cells by RT-PCR. 
Amplicons visualised on one percent low melting point agarose gel and purified for 
Sanger sequencing. A 100 bp DNA ladder was used to estimate the PCR products.  
 
In region 2, three newly identified exons between exons 7 and 10 are shown in 
red colours, exons 8b,8c and 9b (Figure 5.3). These correspond to human exons 
13, 14 and 16 respectively, the alignments are shown in Appendix 9.4. The 
difference between the isoforms involves the presence or absence of exons 8b, 
8c, 9 and 9b: none of these exons were present in short isoform B (119bp), while 
isoform C contains the exons 9 and 9b, and isoform D contains all newly identified 
exons along with exon 9. Exon 7 and 10 are present in all isoforms (Figure 5.3; 
Appendix 9.5 to 9.8). 
 
 
 
 
100 bp 
DNA 
Ladder 
             Tcf7l2 
1F & 2R         7F & 10 R 
110 bp (B) 
210 bp (C) 
280 bp 
340 bp (D) 
100 bp 
200 bp 
300 bp 
400 bp 
500 bp 
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Figure 5.3: A schematic presentation of three novel primary Tcf7l2 transcript 
variants in the pancreatic β cell line INS1 in region 2. Three new novel exons in this 
region are 8b,8c and 9b; are shown in red colour. 
 
5.2 The splice pattern of Tcf7l2 on glucolipotoxic conditions 
 
We then examined the expression of Tcf7l2 isoforms following GLT treatment, 
focussing on region 2 as we have not found any isoforms in region 1. The first 
replicate, both control and GLT, from each of the four independent experiments 
performed were analysed.  
 
Red = novel exon 
‘A’ is the database sequence 
Rat 
genomic 
Tcf7l2 alternative transcripts in INS1 cells 
7 
7 
7 
7 
8c 
8 
8 
8 
8b 
8 
variant 
B 
A 
C 
D 
PCR/bp 
119 
193 
220 
342 
9 9b 
9 
9b 9 
10 
10 
10 
10 
9b 8b 8c 1 2 3 4 5 6 7 8 9 10 
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Figure 5.4: Amplification of Tcf7l2  splice variants in region 2 both in control and  
altered metabolic conditions by RT-PCR. Amplicons visualised on one percent low 
melting point agarose gel and purified for Sanger sequencing. A 100 bp DNA ladder was 
used to estimate the PCR products.  Estimatedd band sizes are shown in the figure.  
 
After running the RT-PCR amplicons on 1% agarose gel (Figure 5.4), up to eight 
variants in GLT and six in control were observed.  Due to time constraints, only 
four were successfully sequenced for both control (C1, C2 and C3 and C6) and 
GLT (G1, G2, G3 and G6). A summary of this analysis is shown in Table in 
Appendix 9.10.  
 
Based on our findings above, we analysed the changes in expression of those 
alternatively spliced isoforms in altered metabolic conditions by comparing them 
with control on four percent agarose gel. As indicated in Figure 5.5, a shift to 
lower molecular weight transcript was observed after GLT treatment, where 
expression of short isoforms B and C went up and isoform D went down (Figure 
5.5).  Four independent experiments were carried out. In future mRNA (isoforms) 
quantification should be carried out to confirm this analysis. 
 
100 bp 
200 bp 
300 bp 
400 bp 
500 bp 
C1/110bp (B)p 
180/190bp (A)p 
C2/200b
p
C3/210bp (C)  
240/250 bp 290bpp 
C6/350bp (D)p 
490 bp 
G1/105bp (B) 
p
G2/190 (A) 
bpp 
G3/205bp (C) 
270bp
p 
300bpp 
G6/310bp (D)p 
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Figure 5.5: Shift to lower molecular weight transcript after GLT treatment. 
Representative image of four independent experiments, showing the first replicon of first 
experiment (Control and GLT treated). Tcf7l2 splice variants on high sugar and free fatty 
acids and compare them with controls. Four independent experiments (Appendix 9.11 
B). 
 
5.3 Discussion 
 
In this experiment, we have successfully identified three new different 
alternatively spliced products in rat Tcf7l2, named as isoform B, C, and D along 
with discovering three new novel exons, namely 8b, 8c and 9b. 
In humans, protein isoforms formed by AS of TCF7L2 exerts a distinct role 
depending on the exons present on that isoform and that may affect the β cell 
function and survival (Le Bacquer et al, 2011). They have demonstrated that 
isoforms containing the combination of exons 13, 14 and 15 produced different 
ORF and overexpression of this full length TCF7L2 had the protective effect on β 
cell survival and function. On the other hand, overexpression of short variant 
(deficient of exons 13,14, 15 and 16) induced impaired insulin secretion and 
apoptosis in human islets (Weise et al, 2010; Le Bacquer et al, 2011). We have 
already shown that rat exons 8b, 8c, 9 and 9b are aligned with human 13, 14, 15 
and 16 (Appendix 9.4). In a comparison TCF7L2 transcript analysis published by 
Le Bacquer et al (2011), we found that short isoform B in rat pancreatic β cells 
are devoid of exons 8b, 8c, 9 and 9b and overexpressed on altered metabolic 
down 
up 
up 
Effect of GLT 
GLT CON LAD 
119 
193 
220 
270 
300 
342 
450 
490 
B - 
A - 
C - 
D - 
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conditions (Figure 5.5) which may induce β cell apoptosis under this altered 
conditions rather than low expression of isoform D (containing exons 8b, 8c, 9 
and 9b) which in normal condition may enhance insulin secretion and has a 
protective effect on β cells survival but these are all suggestive roles, the 
biological effect of those isoforms in rat have not been tested yet (Figure 5.6).  
 
 
 
 
Figure 5.6: Tcf7l2 variants have distinct activity in islets, a comparison of  isoforms 
between human islets by Le Bacquer et al  (2010) and rat isoforms discovered in 
INS1 β cells. 
 
 
 
 
10 
9 10 
8b 8c 9 9b 10 
Variant (rat) 
B 
A 
C 
D 
9 9b 10 
PCR/bp 
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No effect 
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secretion 
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7 
7 
8 
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*Based on data of comparative transcripts from study in human islets published by Le Bacquer et 
al, 2010. 
75 
 
In summary, we have identified three novel Tcf7l2 isoforms (B, C, D) in  rat with 
the discovery of three novel exons (exon 8b, 8c and 9b) and  we have shown that 
GLT treatment is associated with upregulation of a variant (short isoform B) that 
may be associated with β cell death. This conclusion of the functional 
consequence of Tcf7l2 results is based on comparative isoforms study in 
humans. In future, we need to study the isoforms expression at the protein level 
in rat β cells.  
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Chapter 6- Exon array analysis of alternative splicing events in 
β cells following GLT treatment.  
 
The aim of the exon array performed in this section was to identify changes in 
gene splicing induced by GLT treatment of β cells at the global level, and to the 
main cellular pathways affected by alternative splicing. 
 
RNA previously isolated as part of the qRT-PCR analysis (chapter 4) was used 
for hybridisation to Affymetrix Clariom D exon arrays (see method section 2.4). 
Single replicate control and GLT samples from each of the two experiments were 
submitted to the Genomic Centre at King’s College London for hybridisation. 
Analysis was performed using ‘Transcriptome Analysis Console software (T.A.C; 
Thermo Fisher Scientific), as described in the methods. Clariom D is a step up 
from a conventional array because it provides a highly detailed view of 
transcriptome and a faster path to actionable results, investigating altered 
pathways from well-annotated genes, enables rapid discovery of coding and non-
coding genes, exons, splice variants and rare transcripts, able to deliver the 
accuracy in gene expression measurements throughout the transcriptome by 
sequencing on a HighTM2000 system (ThermoFisher Scientific). 
 
CEL files (raw data) were processed using a modification of the normalisation 
method ‘Robust Multi-array Average’ (SST-RMA). Differences arising from inter-
experiment variation were reduced by using the ‘batch effects’ setting during 
processing. The results of the data normalisation process can be illustrated using 
box plots as shown in Figure 6.1.  
 
The signal box plot is based on either CHP or CEL files data before normalisation. 
The purpose for examining box plots is to look for whether individual array data 
are different from others and, most importantly, from other replicates in the same 
group. It is a useful graph to show the shape of the distribution of the data as well 
as its central value (median) and variability (inter-quartile range, and usually the 
maximum and minimum values). The box plot helps to find outlier samples. For 
77 
 
example, in Figure 6.1, the plots in blue colour are before normalisation and pink 
are experiments after background correction and within array normalisation. The 
plots clearly show that there is no outlier of the samples. 
 
 
 
Figure 6.1: Data normalisation in Signal Box Plot. Normalisation compares between 
CEL and CHP files in Signal Box Plot. The plots (pink) clearly show that there is no outlier 
of the samples, the median values are similar across the array and the data distribution 
is normal after normalisation. 
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6.1 Gene level analysis 
 
Default criteria was used for the gene filtering process and the criteria was: fold 
changes >2 or <-2 and p value <0.05. With this default filtration, the total number 
of genes passed through the filter was 68,842. A total of 911 genes were 
differentially expressed following GLT treatment, among them 402 genes were 
upregulated, and 509 genes were downregulated. The pie charts are showing the 
distribution of differentially expressed genes in altered metabolic conditions 
(Figure 6.2). 
To further compare transcript expression between control and treated samples, 
scatter and volcano plots were generated. Figure 6.3 shows genes that are 
upregulated (red) and downregulated (green) in GLT compared to control 
conditions; the grey transcripts were filtered out by the default criteria. The 
volcano plot (Figure 6.3) combines statistically significant p values and fold 
changes, allowing quick visual identification of thousands of datapoints between 
two conditions. The highly significant values are found at the top of the plot. Due 
to quick visual identification of thousands of replicates results, it is very popular 
among genomics and metabolomics (Li, 2012). 
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Figure 6.2: Pie charts showing a gene view summary of differentially expressed 
genes in metabolic conditions.  Based on default filter criteria, the analysis is showing 
the breakdown of a total of 911 differentially expressed genes in glucolipotoxic 
conditions, of which 402 are up-regulated genes and 509 are down-regulated genes. 
The pie chart provides the percent of type of transcripts within the differentially expressed 
genes for example, coding (protein coding transcripts), non-coding, precursor-microRNA 
(gene contains microRNA precursor), pseudogenes, ribosomal (gene contains only 
rRNA), small RNA, tRNA and unassigned (locus type cannot determine based on source 
data). 
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This analysis shows that the number of genes that are highly differentially 
expressed is quite low, and the statistical analysis performed by the software 
indicated that there are no gene expression changes that exceed correction for 
genome-wide significance (FDR<0.05). This is not unexpected given the very 
small sample number, since this experiment was designed to gain initial insight 
into pathways affected by alternative splicing rather than as an end-point analysis 
for gene expression changes. Interestingly, Elavl1 was upregulated 1.8-fold in the 
array analysis, consistent with the qRT-PCR analysis described in section 4.8. 
The rest of the SFs (Table 4.6) were also similar at the gene level to the Clariom 
data. 
As shown in Table 6.9, a Wiki pathway, which is a website that is maintained by 
the biological community that shows biological pathways, analysis of the 
Figure 6.3: Volcano plot of differentially expressed 
genes under GLT conditions (Con vs GLT). For volcano 
plot, significance p value versus fold change on the y and x 
axis; n=2. Each dot represents a gene dot. The dot 
represents a gene; red dots are genes overexpressed and 
dots in green line are downregulated on glucolipotoxic 
conditions. Some top regulated genes are highlighted in 
figure. 
Uc008bi9.2 
KnowTID 
Non-coding 
Cpne9 
Slc9b2 
Pre-miRNA 
Ppp1r3c 
klawchee 
S100a4 Chdh 
Ceacam1 
LOC102547067 
Ptch1 blawcho 
NONMMUG015389 
Oxct1 
flady 
zyloy 
Guca2b 
Txnip 
Plce1 
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differentially expressed genes meeting both fold change and significance criteria 
shows expected changes in lipid/cholesterol and cellular metabolism as well as 
changes in the MAPK signalling pathway. In Wiki pathways, genes are ranked 
based on tissue expression profile.  
Table 6.9: Summary of some top hit metabolic and apoptotic enzymes in 
WikiPathways analysis. 
 
Signalling 
pathway 
Genes 
differentially 
expressed 
Description Regulation on 
GLT 
Cholesterol 
Biosynthesis 
Lss Involved in cholesterol 
biosynthesis 
up 
Mitochondrial 
LC-Fatty Acid 
Beta Oxidation  
Acadl Fatty acid beta 
oxidation 
Down 
Lipid 
metabolism 
Gpd1 Involved in 
carbohydrate 
metabolic process 
Down 
TCA cycle Pdhb Involved in acetyl CoA 
biosynthetic process 
from pyruvate 
Down 
Cell Cycle Abl1, Ccnd2 
(also 
downregulated 
in Wnt 
signalling 
pathway) 
Involved in cellular 
response to oxidative 
stress, found in 
endoplasmic 
reticulum/ 
Involved in cellular 
response to insulin 
stimulus 
Down 
Fatty Acid 
Biosynthesis 
Acaca  Acetyl CoA metabolic 
process, FA 
biosynthesis process, 
insulin signalling 
pathway and 
associated with fatty 
liver and insulin 
resistance 
Down 
Fatty Acid 
Biosynthesis 
Acly FA metabolic process Down 
MAPK Signalling 
Pathway 
Rasgrp2 Ca ion binding and 
positive regulation of 
GTPase 
Down 
MAPK Signalling 
Pathway 
Ntrk1 Participates in 
apoptotic cell death 
Up 
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MAPK Signalling 
Pathway 
Cacna1a Involved in calcium 
channel voltage 
dependent processes 
Down 
 
6.2 Analysis of enriched Pathways 
 
The program we used for this analysis was PANTHER (see Method Section 2.4). 
We uploaded our 911 differentially expressed genes (Section 6.1) and identified 
the enriched pathways of molecular functions, cellular components and biological 
process as well as the results are displayed in a pie chart. 
 
6.2.1 Recognition of molecular functions and cellular components in DE 
genes 
 
Figure (6.4) shows the molecular functions of differentially expressed genes on 
altered metabolic conditions. Among those DE genes, the functions mostly 
affected by glucolipotoxicity were catalytic activity, binding, receptor and 
transporter activity. 
 
 
Figure 6.4: The pie chart represents the enriched molecular functions among the 
differentially expressed genes on GLT. The analysis indicates the association of 
differentially expressed genes with the molecular functions. 
 
Catalytic activity such as enzyme regulator activity, transferase activity and 
oxidoreductase activity could be affected due to metabolic conditions. Another 
enriched molecular function for DE genes was binding activity, which is in line 
antioxidant activity   
catalytic activity   
binding 
channel regulator activity 
receptor activity 
signal transducer activity 
structural molecule activity  
translation regulator activity 
transporter activity 
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with many molecules implicated in the impairment of calcium ion binding (MAPK 
signalling pathway; Table 6.9), calcium dependent phospholipid binding, 
carbohydrate, lipid, nucleic acid, nucleotide, oxygen and protein biding etc in 
insulin secretion and metabolic pathways, and consequently receptor activity and 
transporter activity, for example, glucose and lipid transporter activity along with 
transmembrane transporter activity are also impaired in β cells in T2D (Bagnati 
et al, 2016 and Saltiel and Khan, 2001). 
 
Figure 6.5 shows the majority of differentially expressed genes are located on 
cell part (any constituent part of the cell) and on cell junction (multiprotein 
complexes that provides communication between a cell and extracellular matrix 
and between cell-cell communication) which is in line with the impairment of 
insulin secretion, glucose transport, and consequently receptor and glucose 
transporter activity are impaired in T2D (Saltier and Khan, 2011). Macromolecular 
complexes for example, ribonucleoprotein complexes (e.g. RBPs), protein 
complexes and protein-DNA complexes are affected by altered metabolic 
conditions (Chapter 4). 
 
 
Figure 6.5: The pie chart presenting the enriched cellular component, where a 
gene acts in the cell, among the differentially expressed genes in high glucose 
and FFAs conditions. 
 
 
 
cell junction 
cell part 
extracellular matrix 
extracellular region 
macromolecular complex 
membrane 
organelle 
synapse 
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6.2.2 Identification of enriched biological process 
 
The enriched biological process (Figure 6.6), some biological phenomena that 
affects the state of an organism, is mostly affected in high sugar and fatty acids 
conditions were cellular and development process such as cell communication, 
cell cycle, cell growth, cell proliferation, cell recognition, cellular component 
movement, cell differentiation and death. These functional enrichments in 
differentially expressive genes could be explained by the impairment of β cell 
function and proliferation. Impairment in the cell cycle and cell growth could lead 
β cell death or trigger apoptosis. The over expression of Tcf7l2 short isoform 
(Section 5.2) and Elavl1 (Section 4.7) support the detrimental effects of 
glucolipotoxicity in β cell. The growth curve analysis also supports the adverse 
effects of high sugar and fatty acids on β cell growth and viability. DE genes in 
biological process, such as the homeostasis process, reflects impairment of 
glucose homeostasis in altered metabolic conditions. 
 
Differentially expressed genes on GLT conditions in localisation such as RNA 
and protein localisation and transport, are in line with the finding of the 
overexpression of the stress-associated mRNA processing and stability gene 
Elavl1 in β cells (Section 4.7). The Wiki pathways analysis (Table 6.9) supports 
the enriched functions of DE genes in metabolic processes affected by 
glucolipotoxicity. 
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Figure 6.6: Enriched biological process involved in altered metabolic conditions. 
The pie chart is representing biological process affected by glucolipotoxicity and another 
dimension of biological function expressed by differentially expressed genes under that 
conditions. 
 
6.3 Top hit results associated with diabetes, metabolism and apoptosis 
 
A ‘Comparison Wizard’ is a tool to customise the analysis which can decrease 
the number of contrasts to simplify the results. The contrast based on the 
question queries the differential expression between two groups, for example, the 
‘control’ and ‘GLT’ groups. By using this tool, we analysed our data to find the 
differential expression genes on GLT conditions. The top hit results have been 
summarised (Table 6.10) with corresponding fold changes and p values in 
conditions of high glucose and free fatty acids compared to controls. The results 
suggest the involvement of the specific genes in glucose metabolism (glycolysis), 
calcium and calcium signalling pathways, insulin signalling pathways, adipose 
tissue development, cell apoptosis regulation process and associate with T2D. 
 
 
 
biological adhesion 
biological regulation  
cellular component organisation or biogenesis 
cellular process 
developmental process 
growth  
immune system process 
localization  
locomotion 
metabolic process  
multicellular organismal process 
reproduction 
response to stimulus 
rhythmic process 
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Table 6.10: List of top hits array results on GLT conditions in β cells; n=2 
(con vs GLT). 
 
Gene 
name 
Description Regulation Fold 
Change 
P value 
Ppp1r3c Involved in regulation of 
glycogen biosynthetic 
process and glycogen 
catabolic process; 
participates in insulin 
signalling pathway. 
Down 3.28 0.0003 
Slc9b2 Interacts with nuclear 
gene encoding 
mitochondrial protein; 
integral component of 
membrane 
Down 4.04 0.0004 
Ptch1 Encode a protein that 
exhibit cholesterol 
binding; involve in 
response to drug and 
mechanical stimulus 
Up 2.82 0.0004 
S100a4 Calcium binding protein; 
participates in calcium/ 
calcium mediated 
signalling pathway 
Down 6.86 0.0006 
Oxct1 Involved in adipose tissue 
development/ participates 
in ketone bodies 
metabolic pathways/ 
associates with T2D 
up 3.93 0.0006 
Guca2b Participates in calcium 
and calcium signalling 
pathway 
Down 3.02 0.0006 
Lgals5 Encodes a protein that 
exhibits carbohydrate 
binding  
Down 2.38 0.0008 
Plce1 Involved in activation of 
MAPK activity; 
participates in calcium 
and calcium mediated 
signalling pathway 
Down 2.64 0.0008 
Txnip Involved in apoptosis 
regulation process 
Down 6.12 0.001 
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6.4 Exon level analysis of alternative splicing 
 
For the exon level analysis, which allows identification of alternative splicing 
events in a specific gene, we again used the default criteria of an exon splicing 
index (The fold change of normalised expression levels for condition 1 versus 
condition 2 of the PSR or junction’s expression level  which is normalised to the 
gene’s expression level) of +/- 2 fold, and an exon p value <0.05. Of the 68,599 
genes, 8,958 (13.06%) met these criteria of exon level changes (Figure 6.4). 
Exon p value is the probability that there is no actual difference in the expression 
for the PSR and any observed difference is due to variance in the measurement 
(TAC 4.0.1 user guide; Thermo Fisher Scientific). 
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A) 
 
B) 
Events Count 
All 77 
Alternative 5' Donor Site 24 
Intron Retention 19 
Cassette Exon 19 
Alternative 3' Acceptor Site 15 
C) 
 
Figure 6.7: Exon expression analysis of alternative splicing on glucolipotoxic 
conditions (control vs. GLT). A) The pie chart provides a breakdown of genes by 
groups meeting the filter criteria B) Around 77 events were tested and genes above 13% 
passed the filter which means it can be considered to be alternatively spliced following 
GLT treatment in rat β cells C) the breakdown of identified standard alternative splicing 
events i.e. cassette exon, mutually exclusive exons, alternate 5’ donor site, alternate 5’ 
acceptor site and intron retention. 
 
However, only 74 of these genes were assigned an exon score (consensus 
alternative splicing event score), representing the set of genes that are most likely 
to present a genuine alternative splicing event. The score is value from 0 to 1, 
where 1 represents a high probability for the event. Of these 74 genes, the top 5 
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were: Txnip, Diablo, Cyp4f1, Tsc22d1 and Cox15. Three of these (Txnip, Diablo, 
Tsc22d1) are directly involved in the regulation of apoptosis, while Cyp41 is 
involved in cytochrome c synthesis, potentially providing an additional link to the 
mitochondrial pathway of apoptosis (gene + exon; total 911 filtered genes).  
The structure view of the TAC software was used to visualise the specific splicing 
events identified, as shown in Figures 6.5, where a cross-out box represents no 
data, a diagonally crossed-out box represents that is not expressed in either 
condition and PSR/junction indicates by box containing splicing index number on 
the top. Isoforms are displayed in table below the structural view; transcript 
isoforms are sorted as ‘up regulation’ on GLT conditions at the top and ‘down 
regulated’ are at the bottom. The colour coding is associated with exons; 
transcripts containing red exons are overexpressed and green exons are 
downregulated (Figure 6.5). 
A) 
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B) 
 
C) 
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D) 
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E)  
 
 
 
Figure 6.8: Exon expression analysis of AS of top 5 genes on GLT conditions. 
Image showing the normalised view of exon splicing.  For each PSR/junction, fold 
change measurement is based on colour and the intensity of colour reflects the amount 
of fold change, with the pink line showing a selected sample, the red being control and 
the green GLT. Transcript isoforms can be viewed based on database selection, we have 
sorted isoforms based on Affymetrix database. A) AS events of Txnip which involved in 
positive regulation of apoptotic process, cell cycle proliferation and response to calcium 
ion. B) As events of Diablo involved in intrinsic apoptotic signalling pathway in response 
to oxidative stress. C) As events Cyp4f1 response to toxic substance and participates in 
cytochrome P450 monooxygenase mediated pathway of arachidonic acid metabolism 
and arachidonic acid metabolic pathway. D) AS events of Tsc22d1 involved in positive 
and negative regulation of apoptotic process and positive regulation of cell proliferation. 
E) AS events of Cox15 involved in oxidative phosphorylation pathway and associated 
with Cytochrome-c Oxidase deficiency. 
  
93 
 
6.4 Discussion 
 
The Clariom D array provided a complete view of all the differentially expressed 
and alternatively spliced genes in a single experiment. The main purpose was to 
discover novel alternatively spliced molecules that could be involved in the 
impairment of β cell function after exposure to high concentrations of glucose and 
fatty acids and use these results in future experimental designs. We initially 
focused on the general characterisations of differentially expressed genes and 
pathways analysis to identify the novel mechanism affected by GLT. 
 
The pathway analysis has shown the most dysregulated genes which ultimately 
reflects the pathways that are differentially affected by glucolipotoxicity. For 
example, differentially expressed or dysregulated genes observed in cholesterol 
biosynthesis, mitochondrial long chain fatty acid beta oxidation, TCA cycle and 
fatty acid biosynthesis which reflects the consequence of altered metabolic 
conditions relevant to T2D in pancreatic β cells. On the other hand, differentially 
expressed genes in the cell cycle, Wnt signalling pathway and MAPK signalling 
pathway reflect the adverse effect of GLT on β cell proliferation, insulin sensitivity 
and insulin resistance; these pathways are also found to be affected in obesity, 
hyperlipidaemia, hypertension and T2D (Saltiel and Khan, 2001). Our Wiki 
pathways analysis results and the top hit array results suggest the involvement 
of the specific genes (DEs) in glucose metabolism, calcium and calcium signalling 
pathways, insulin signalling pathways, adipose tissue development, cell 
apoptosis regulation process and associate with T2D. The identification of 
enriched pathways analysis has also shown the enriched molecullar, cellular and 
biological functions of DE genes. 
 
Our exon level analysis of alternative splicing results has shown the association 
of alternative splicing of top five genes: Txnip, Diablo, Cyp4f1, Tsc22d1 and 
Cox15, among them Txnip, Diablo, Cyp4f1 and Tsc22d1 are directly involved in 
the regulation of apoptosis suggesting the association of β cell apoptosis with 
alterted metabolic conditions in T2D. Whereas altered isofoms formation of 
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Cyp4f1 and Cox15 reflects the alternative splicing pattern changes to 
physiological and environmental stressors.  
The biological replicates (n=2) for exon-array analysis are not enough for a 
powerful statistical test over fold changes threshold for selecting DE genes; the 
threshold incorporates variation between measurements, estimate for error rate, 
detection of minor changes and the ranking of DE genes. In future, more 
replicates should have been analysed for more powerful statistical results. 
 
6.4 Limitation: 
 
• Only two replicates in each category were analysed for genome-wide 
analysis that underpowers the Clariom genome wide analysis.  
• Although multiple testing has not been applied, it needs to be recognised 
that over 68,000 transcripts tested from where 700 could appear positive 
by chance at p= 0.05 and that is why these findings should be viewed with 
caution. Same issue of multiple testing needs to be recognised for specific 
isoforms testing.  
• Need to look in more detail at the type of splicing event being indicated for 
top 74 AS hits which is essential to assess what impact these treatments 
have had on the splicing patterns in rat β cells. 
• No alternative splicing events were analysed for Tcf7l2 in this array since 
only a single transcript is reported in the database.  
• Needed to validate array hits by RT-qPCR but due to time constrains we 
could not validate the DE and alternatively spliced genes under metabolic 
conditions. 
 
In conclusion, our transcriptome analysis has shown that metabolic conditions  
alter the alternative splicing regulation of some apoptotic genes which support 
our finding of Elavl1 overexpression on these conditions which suggests that high 
sugar and fatty acids may contribute to β cell loss in some peole with type 2 
diabetes. 
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Chapter 7- Discussion 
 
According to International Diabetes Federation (IDF) approximately 425 million 
adults were suffering from diabetes in 2017 and predicts that the number will 
increase to 629 million by 2045. This issue needs to address urgently. Both 
genetics and epigenetics are interacting factors where unhealthy lifestyle 
influences. We hypothesized that the metabolic conditions are associated with 
T2D may affect the regulation of alternative splicing, a regulated process during 
gene expression that results in a single gene coding for multiple proteins and a 
crucial mechanism for gene regulation and for proteomic diversity. Little is 
currently known about the effect of metabolic changes that exist in many people 
with T2D on splicing in β cells. Therefore, we aimed to investigate how this may 
link to decline of β cell mass and function which can pave the way to future studies 
in order to develop therapeutic strategies that are able to restore β cell function 
in T2D. 
   
Based on our research design - at first, we wanted to test the effect of 
glucolipotoxic conditions on β cell viability. We replicated in vitro diabetic 
extracellular glucolipotoxic conditions in INS1 rat pancreatic β cells (insulinoma) 
and treated them with GLT media (Bagnati et al, 2016) to analyse the toxicity 
effect on β cell growth and compare that with control by a statistical end-point 
growth analysis. We found that this condition decreased the viability of INS1 cells 
both in serum free and complete. A statistical end-point analysis has shown a 
significant decrease in cell numbers in both serum free (p=0.0006, n=6) and 
complete media (p=0.002, n=6) in 2/3 experiments, suggesting that metabolic 
conditions may affect the pancreatic β cell growth. A previous study by Zhou et 
al (2014) demonstrated that an increased apoptosis with progressive activation 
of caspase 3 happened in INS1 cells when treated with 30 mM glucose and 200 
µM palmitic acid, supporting our outcome in terms of decrease viability of INS1 
cells under our experimental toxic conditions (INS1 cells treated with 27mM 
glucose, 200 µM palmitic acid and 200 µM oleic acid), although they did not use 
oleic acid and they used an extra 3 mM glucose in their experiment. It is known 
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that there is an antagonism between saturated and unsaturated fatty acids 
(Gehrmann et al, 2015) but it is more physiological to use palmitic and oleic acid 
both in in vitro experiment.  Our growth curve experiment was well designed 
because there was no missing data from replicates, timepoints were equally 
spaced, data was normally distributed, and experiment was repeated 2/3 times 
with six technical replicates. Hence, growth curve analysis suggests that INS1 
average cell area decreased under altered metabolic conditions. 
 
The growth curve titration helped us to choose a timepoint (46 hours) to analyse 
our selected panel of splicing regulators on GLT conditions by RT-qPCR.  Among 
the selected splicing factors our data analysis has demonstrated the 
overexpression (p=0.04) of HuR family gene Elavl1 under altered metabolic 
conditions.  
 
Therefore, in this study, we have shown that metabolic conditions associated with 
T2D, specifically high levels of glucose and free fatty acids in presence of control, 
affect the global regulation of alternative splicing in β cells. Specifically, 
expression of the mRNA processing and stability regulator Elavl1 is upregulated 
by GLT treatment of INS1 β cells in vitro. No study of Elavl1 expression under 
GLT conditions in INS1 β cell has been published yet. 
 
Despite HuR’s predominant nuclear localisation and extensive characterisation, 
the functions of this family genes as splicing regulator still not identified yet. One 
of the reasons may be no target sequences for this regulatory gene has been 
discovered yet (Izquierdo, 2008). 
 
Elavl1 has previously been shown in other cell types to regulate the alternative 
splicing of the apoptotic death receptor Fas and Tra2β, itself an important trans-
acting regulator of alternative splicing. Elavl1 is also known to regulate mRNA 
stability of target genes under conditions of stress. It will be important in the future 
to determine the role of Elavl1 in β cells. This has not previously been examined, 
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although work by Mateu et al (2017) has shown that siRNA knockdown of the 
related family member Elavl4 modulates β cell death. This supports the 
hypothesis that GLT stress in β cells activates a programme of alternative splicing 
events, mediated by Elavl1 upregulation, that activate β cell apoptosis. 
 
We have also demonstrated that reference gene Ppia expression is stable under 
altered metabolic conditions and conversely that Gapdh should not be used as a 
RT-qPCR loading control in this type of study. 
 
Diabetes candidate gene TCF7L2 is an important factor determining T2D risk and 
is known to be regulated by alternative splicing. We investigated whether altered 
metabolic conditions and overexpression of splicing regulatory gene Elavl1 were 
associated with changes in Tcf7l2 isoform expression. We worked with rat INS1 
cell line and there were no splice variants have been reported for rat Tcf7l2 in the 
database. However, in human genomic structure of TCF7L2 consists of 17 exons 
(Database reported 10 exons for rat Tcf7l2) and only four splice variants were 
reported to be expressed in human β cells by Hanson et al, 2010. By an end-
point PCR/ conventional PCR followed by Sanger sequencing we first discovered 
three novel Tcf7l2 isoforms in rat INS1 β cells with the identification of three new 
novel exons (Exon 8b, exon 8c and exon 9b).  
 
Therefore, we, have identified three novel rat isoforms (Isoform B, C and D) of 
Tcf7l2 that are not present in the database, and we have further shown that GLT 
treatment appears to regulate the pattern of Tcf7l2 isoform expression. By 
comparison with the functional analysis of human TCF7L2 isoforms by Le 
Bacquer et al (2011), our data suggests that GLT treatment induces expression 
of a Tcf7l2 isoform (short isoform B) that induces β cell apoptosis. This will require 
further experimental validation but provides further support for the link between 
GLT stress, alternative splicing and β cell apoptosis. Therefore, in future, we need 
to examine the functional consequence at the protein level for all three new 
isoforms in rat pancreatic β cells. 
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The top hit results at the exon level analysis (Microarray) support the involvement 
of the specific genes (DEs) in glucose metabolism, calcium and calcium signalling 
pathways, insulin signalling pathways, adipose tissue development and cell 
apoptosis regulation process associate with T2D. The identification of enriched 
pathways analysis has also shown the enriched molecular, cellular and biological 
functions of DE genes. On the other hand, Wiki pathway analysis results of DE 
genes have shown the differentially expressed genes in cell cycle, Wnt signalling 
pathway and MAPK signalling pathway suggesting the adverse effect of altered 
metabolic conditions in β cell.  
 
Further evidence supporting our hypothesis was provided by the exon-level 
analysis of alternative splicing at the global level by GLT conditions. Four of the 
top five alternative splicing events (Txnip, Diablo, Cyp4f1 and Tsc22d1) were 
genes linked to the regulation of apoptosis. However, it will be important to 
confirm the induction of these specific splicing events by GLT conditions using 
RT-qPCR, and in the long-term to determine the effect of the induced isoforms 
on β cell apoptosis. 
 
Hence, the exon level analysis is suggesting that alternative splicing pattern 
changes continuously in respose to physiological conditions and environmental 
stressors which activating cells to react many challenges by  differential 
expression of genes and by altering the balance between different mRNA 
isofomrs. 
 
The results of this study have potential relevance for people with pre-diabetes 
and will be important to examine whether similar changes occur in human β cell 
lines, and in β cells isolated from people with diabetes. However, there are 
significant barriers to obtaining such samples, which can only be obtained post-
mortem. However, if supported by future experimental results, this study 
suggests that the AS pathway in β cells, perhaps specifically Elavl1, could 
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potentially be used to promote β cell survival in people with pre-diabetes. This 
will require further experiments to evaluate this possibility, and to identify viable 
approaches to pharmacological regulation and delivery. 
 
In conclusion, this study demonstrates that: 
• High glucose and fatty acid (GLT) metabolic conditions induce expression 
of the RNA binding protein / splicing regulator Elavl1 in β cells. 
•  GLT conditions increase expression of Tcf7l2 transcript variants that may 
induce β cell apoptosis rather than enhancing insulin secretion. 
 
Exon array data demonstrates that GLT treatment induces alternative transcript 
expression of a panel of apoptotic regulatory genes in β cells. This Suggests that 
Elavl1 may be a novel master regulator of alternative splicing of apoptotic genes 
in β cells during altered metabolic conditions, and that alternative splicing of 
apoptotic genes in β cells may contribute to β cell loss in people with metabolic 
syndrome and pre-diabetes. 
 
7.1 Limitation 
 
• To study glucolipotoxicity on the pancreatic β cell, we used the rat INS1 β 
cell line. However, we could have used at least another rat beta cell line 
e.g. RIN, MIN, HIT etc to see if similar changes occur in our study. It would 
be very useful to examine the results in human beta cell line EndoC-βH1 
which can be a part of future study. 
 
• Our data showed the GLT effect on the expression of 13 splicing regulatory 
genes among about 300 SFs. There may be some notable omissions that 
are expressed in β cells for example, some negative trans-acting factors 
hnRNPs (Hnrnpa1 and Hnrnpa2b1) which are found to be associated with 
cancer and ageing in human, should be tested under GLT conditions. In 
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future, it could be interesting to investigate more SFs and the Clariom data 
by selecting and testing SFs in altered metabolic conditions. 
 
• The SFs expression changes were only investigated at 46-hour point, 
could have missed the detection of some important mechanisms at the 
early or at later stage. In future, the results we observed at 46-hour time 
point could investigate at other time points as well to investigate their 
molecular mechanisms at different time point of β cell growth under GLT 
conditions. 
 
• More than one reference gene should be used in relative gene expression 
analysis by RT-qPCR. We have used only one reference gene Ppia in our 
study. In future study we can use more than one reference gene in RT-
qPCR analysis. 
 
• The biological replicates for the analysis of splicing regulators’ expression 
by RT-qPCR under altered metabolic conditions were enough to carry on 
a two-tailed paired sample t-test. However, for a powerful statistical 
analysis biological replicates should be higher. 
 
• The functional consequence of Tcf7l2 isoform results is based on 
comparative isoforms study in humans (Le Bacquer et al, 2011). Despite 
rodent and human genome share high similarity there are some species 
related differences. To confirm this functional effect we need to see the 
protein level expression in rat β cells. It can be a part of future study. 
 
• The Clariom analysis for genome wide analysis with only 2 replicates in 
each category is not enough for a powerful statistical analysis.  Although 
the purpose of exon array analysis was to have a future experimental 
design, however for this kind of high throughput genome wide analysis the 
biological replicates should be higher. 
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• The top hit results of differentially expressed genes and alternatively 
spliced isoforms has to be confirmed by RT-qPCR. Due to time constrain 
we were not able to carry on that validation work but could be done in 
future. 
 
7.3 Conclusion 
 
This study demonstrates that the metabolic conditions existing in many people 
with type 2 diabetes may cause aberrant alternative splicing in β cells increasing 
susceptibility to apoptosis and subsequent β cell loss. 
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Chapter 9-Appendix 
 
 
9.1 qPCR fold changes calculations for Elavl1, control vs. GLT (Ppia as a 
reference gene) 
 
 
 
FOLD CHANGES CALCULATIONS FOR 
Elavl1 (Exp-1) 
      
   
ΔCq neg 
ΔΔCq 
fold 
changes 
to 
control 1 
      
Sample 
Name 
Elavl1  
Mean 
Ppia  
mean 
Elavl1 Elavl1 Elavl1 Mean sd t-test   Elavl1 
Mean 
Ppia 
mean 
CONTROL 
RT 1 
23.2 20.6 2.6 0.0 1.00       
 
    
CONTROL 
RT 1 
                
 
    
CONTROL 
RT 2 
23.4 21.0 2.4 0.3 1.20 1.1 0.09 0.052557 CON 23.3 20.9 
CONTROL 
RT 2 
                
 
    
CONTROL 
RT 3 
23.3 21.0 2.4 0.2 1.18       
 
    
CONTROL 
RT 3 
                      
GLT RT 1 22.3 20.0 2.3 0.3 1.26       
 
    
GLT RT 1                 
 
    
GLT RT 2 22.5 20.9 1.6 1.0 2.02 1.8 0.38   GLT 22.5 20.7 
GLT RT 2                 
 
    
GLT RT 3 22.7 21.1 1.6 1.1 2.09       
 
    
GLT RT 3                       
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9.2 qPCR analysis of splice factors on GLT conditions (Ppia as a reference 
gene) 
 
Gene name Paired t-test (Ppia, a 
reference gene) 
N number 
Rbfox2 0.9 3 
Nova2 0.7 3 
Elavl1 0.04 4 
Elavl4 0.5 3 
Hnrnpf 0.3 4 
Ptbp1 0.2 4 
Srsf3 0.8 4 
Srsf5 0.5 4 
Srsf6 0.7 4 
Srsf10 0.9 4 
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9.2 Human TCF7L2 splice variants in database 
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9.3: Exon sequences for human variant 222 (11/9/17) 
 
>Tcf7l2-201 cdna:protein_coding 
TCATCCATAAGTATGTTTCTGTGAGGTGCAAGCATGGGCGATCCCATTAAGTTTATCCTA 
ATAGATGCTTCAGTAAGGTAAGTTGAGAGAAGGCACAGCTAGGCAGCTGGCTGGTTGCTT 
AGAGGGAGGAGAAGCCATATTCATGGGGGGATGGTGTTAGGGATGGGGACGGTGGGAAGG 
GGCTTCGTAGGAACGCTGCATGAGGAAGCCGTGTTTGAGATGTCCCTCAGGGACCCCAGC 
TGCATGGCAGGGAGGTGTGGAGAATTCTGGGTATGCCTTGGTGACTTGGCCCTCTCTCCT 
CAAGCCTCACCCTGTCCCCCTTTCTTCCTGGCAGCAGAGCCCCCTCCCTTGCTGCACTCA 
GGGCCATGCCTGTCCGCACTTCTACACCCCCTCAGACTTCACTGTCAGCACGCAAGTCTT 
CAGGGACACGAAAAGCAGCCACTCCTTACAAAAGGTTGGGGAGCCCTGGTTTCTGGAGTC 
GAACAAAGTGCCGGTGGTGCAGCACCCCCACCATGTCCACCCACTCACACCTCTCATCAC 
GTACAGCAATGAACACTTCACCCCGGGAAATCCACCTCCGCACTTACCAGCTGACGTAGA 
CCCCAAAACAGGAATTCCACGGCCTCCGCACCCTCCAGATATCTCTCCATATTACCCGCT 
GTCGCCCGGCACCGTAGGACAAATCCCCCATCCGCTAGGATGGTTAGTACCACAGCAAGG 
TCAGCCTGTGTACCCAATCACGACAGGAGGATTCAGACACCCCTACCCCACAGCGCTGAC 
AGTCAACGCGTCTATGTCTAGGTTCCCTCCCCACATGGTCCCTCCCCATCACACTCTGCA 
CACGACCGGAATCCCCCACCCGGCCATTGTCACACCGACAGTCAAGCAGGAGTCCTCACA 
GAGTGACGTCGGCTCACTCCATAGCTCAAAGCATCAGGACTCCAAGAAGGAAGAAGAGAA 
GAAAAAGCCCCACATAAAGAAGCCCCTTAATGCATTCATGTTGTATATGAAGGAGATGAG 
AGCGAAGGTGGTGGCTGAGTGCACATTGAAAGAGAGTGCAGCCATCAACCAGATCCTCGG 
GCGCAGGTGGCACGCCCTGTCCAGGGAAGAACAGGCAAAGTACTACGAGCTAGCCCGGAA 
GGAACGACAGCTTCACATGCAGCTGTACCCTGGCTGGTCTGCACGGGATAACTATGGAAA 
GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGATGCAAATACTCCAAA 
GAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCAGGAG 
AAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGCCTCAGCCCACCCTCTTC 
AGATGGAAGCTTACTAGACTCACCTCCCCCCTCACCGCATCTGCTAGGCTCCCCTCCCCA 
AGACGCCAAGTCACAGACTGAGCAGACACAGCCGCTCTCGCTGTCCCTGAAGCCTGATCC 
TCTGGCCCACCTGTCCATGATGCCTCCACCACCCGCGCTCCTGCTGGCTGAAGCTGCCCA 
CGGCAAGGCCTCTGCCCTCTGTCCCAACGGGGCCCTGGACCTGCCACCTGCCACTTTGCA 
GCCGTCCATGGTCCCTTCCTCATCGCTCGCACAACCATCAACTTCTTCCTTACATTCCCA 
CAACTCGCTGGCTGGGACGCAACCCCAGCCTCTGTCTCTGGTGACCAAGTCTTTAGAATA 
GCTTCGCCTCCTCGTCTTCCGTGCCCCTGCTTGATTGAAGTGTTTCCTTCTGGTTCTTGG 
TTCGCCCTTCCCCCGCTTGGAAAGCCTTTTTTCTTGTTCTTTAATTTTGTGCCACTGTGG 
CTACATGAGTTAATGTTTATGGAGTTCATTGGTCAATATTTGACCCATTCTTATTTCAAT 
TTCTCCTTTTAAATATGTAGATGAGAGAAACCTCATGATTCTACCAAAATTTTTATCAAC 
AGCTGTTTAAAGTCTTTGTAGCGTTTAAAAAAATATATAAATATATATATACATAACTGT 
TATGTAGTTCGGATAGCTTAGTTTTAAAAGACTGATTTAAGGAACAAAAAGAAAAAGAAA 
AGAGAGAGAAGCAACTTTGAAGCACCCTCCAGAAGGAGTTGGTTCTGTATTATTTGTATT 
AAATACGAGCTTGCGAACCAATCATTTCCATCTTGGTATTTAAACCGCGAGGGCACGATG 
AATGCAGTGCCGTTTCTTTCTTTCTTTTTTCCTCCCATGTGAAACAACTTTTATTGTGAT 
GTTACTTGTTATTGTTTAAATGTACAGAAACAAAGGGTTAAAATGTGTTAATATACCTTT 
TTCCATGGTGTTGTTCTTTTTGGGGGGAGGGGACGCTACTCAACATGAATGGAATCAACA 
CTGTTGGACCAGTAGTATTTATTACTTTAGAGGTTGCTTGTCCGTACCTGTCCGTCCGTC 
CAATTTTAAATATTGTTTCCCTTTTTTTTTTGAAACTGTATAAAGTCAACCCCCCCAACA 
TAAGCATCTTATATACAACAACTCATTTGTACAAGGTTTTTAAGTTTATATATAAATTGT 
GTATATATTTTTTTGTTTCCTTTTCTTGACTTTTCGTTTGTTTGTTTGTTTCTGTATAAA 
ACCCAGATGCCACCAAATGGACATTGATAGCTGCATTAAGGATCAGTAGCATTAACAAAA 
GTTGCTTTAAAAGCCATTACGTAAAACAAGACTTGAACATTAGCGAGAGGGTCGAGCAGA 
GCAGCCGTGGGAACCACCCCGTTTCCCCTTGGACCTCCTAGTCAATTACCCTGTGCTCTT 
AGAACATGGACTGACCGTGTGCAAAACTTTTTATGTGCCAAAATTCTCAGTGACTTTAGC 
TTTCTCCCTCCTTTTTGATGCCGTACTTTCTGTTCGCCATGTTTTGCTGTGATGTTACAT 
AGATAGATTTGTATGTAGTTTTAATGTCACCTATAACAAAATGTGTTTGGTAGCAGACTG 
TCCAGAAAGCATTTTAAATGAAGAGGTCTAAACCCTTAAGGGCCAAAAATTCTGTATATT 
AGATTACTCTTAAAATGAAAAAGAAAAAAAGTAAAAAAAAAAAAAACCCAGCTGCCGCTT 
CTGTGTACAAGTATGACATACGAGTAGGTAGCGAACTTTAAAAACAAGAGAACCTAGGCA 
TGCCGATGTTGTAAAATGCTGTATAAAGCCGAGACCTGTCTTTTCAGTGCCATCGTAGTT 
GACATGAAGCGATTGTAAAACTGTCTCCGGTTTTCTCTGGTTTATTAAAATGCTAACTAT 
AACAATTTTTTTTTGTGAATACTTTGAATGTTTCCTAACAGTTGTGGTGTTACCGTTCTG 
TTTGATGCTTATTCCAAGTTCATTTTTGGATGGTTTGGAAGCCATTTTGTAATGAATAAA 
TGTCCATGCTGTACAGTATCTGTAGCATGCCGTTCTGGATTAATAAAAGCAACTTAGTAT 
GTGCAG 
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9.4: human and rat (TCF7L2) exons alignment results. 
 
Alignment between human exon5 and rat exon 1: (Date of alignment 130818) 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
rat1      TCATCCATAAGTATGTTTCTGTGAGGTGCAAGCATGGGCGATCCCATTAAGTTTATCCTA 60 
hu5       ------------------------------------------------------------ 0 
                                                                       
 
rat1      ATAGATGCTTCAGTAAGGTAAGTTGAGAGAAGGCACAGCTAGGCAGCTGGCTGGTTGCTT 120 
hu5       ------------------------------------------------------------ 0 
                                                                       
 
rat1      AGAGGGAGGAGAAGCCATATTCATGGGGGGATGGTGTTAGGGATGGGGACGGTGGGAAGG 180 
hu5       ------------------------------------------------------------ 0 
                                                                       
 
rat1      GGCTTCGTAGGAACGCTGCATGAGGAAGCCGTGTTTGAGATGTCCCTCAGGGACCCCAGC 240 
hu5       ------------------------------------------------------------ 0 
                                                                       
 
rat1      TGCATGGCAGGGAGGTGTGGAGAATTCTGGGTATGCCTTGGTGACTTGGCCCTCTCTCCT 300 
hu5       ------------------------------------------------------------ 0 
                                                                       
 
rat1      CAAGCCTCACCCTGTCCCCCTTTCTTCCTGGCAGCAGAGCCCCCTCCCTTGCTGCACTCA 360 
hu5       ----------------------------------CAGAGCCCCCTCCCTTGCTGCACTCA 26 
                                            ************************** 
 
rat1      GGGCCATGCCTGTCCGCACTTCTACACCCCCTCAGACTTCACTGTCAGCACGCAAGTCTT 420 
hu5       GGGACATGACTGTCAGCACTTCTACCCCCCCTCAGACTTCACTGTCAGCACTCAAGTCTT 86 
          *** **** ***** ********** ************************* ******** 
 
rat1      CAGGGACACGAAAAGCAGCCACTCCTTACAAAAGGTTGGGGAGCCCTGGTTTCTGGAG 478 
hu5       CAGGGACATGAAAAGGAGCCACTCCTTACAAAAAGTTGGGGAGCCCTGGTGTATTGAG 144 
          ******** ****** ***************** **************** * * *** 
 
 
Human exon 6 matched with rat exon 2: (Date of alignment 11.09.17) 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon6        TCTAACAAAGTGCCAGTGGTGCAGCACCCTCACCATGTCCACCCCCTCACGCCTCTTATC 60 
rat_exonn2      TCGAACAAAGTGCCGGTGGTGCAGCACCCCCACCATGTCCACCCACTCACACCTCTCATC 60 
                ** *********** ************** ************** ***** ***** *** 
 
hu_exon6        ACGTACAGCAATGAACACTTCACGCCGGGAAACCCACCTCCACACTTACCAGCCGACGTA 120 
rat_exonn2      ACGTACAGCAATGAACACTTCACCCCGGGAAATCCACCTCCGCACTTACCAGCTGACGTA 120 
                *********************** ******** ******** *********** ****** 
 
hu_exon6        GACCCCAAAACAG 133 
rat_exonn2      GACCCCAAAACAG 133 
                ************* 
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Human exon 7 matched with rat exon 3: (Date of alignment 11.09.17) 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon7       GAATCCCACGGCCTCCGCACCCTCCAGATATATCCCCGTATTACCCACTATCGCCTGGCA 60 
rat_exon3      GAATTCCACGGCCTCCGCACCCTCCAGATATCTCTCCATATTACCCGCTGTCGCCCGGCA 60 
               **** ************************** ** ** ******** ** ***** **** 
 
hu_exon7       CCGTAGGACAAATCCCCCATCCGCTAGGATGGTTAGTACCACA 103 
rat_exon3      CCGTAGGACAAATCCCCCATCCGCTAGGATGGTTAGTACCACA 103 
               ******************************************* 
 
Human exon 8 matched with rat exon 4: (Date of alignment 11.09.17) 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon8       GCAAGGTCAACCAGTGTACCCAATCACGACAGGAGGATTCAGACACCCCTACCCCACAGC 60 
rat_exon4      GCAAGGTCAGCCTGTGTACCCAATCACGACAGGAGGATTCAGACACCCCTACCCCACAGC 60 
               ********* ** *********************************************** 
 
hu_exon8       TCTGACCGTCAATGCTTCCATGTCCAG 87 
rat_exon4      GCTGACAGTCAACGCGTCTATGTCTAG 87 
                ***** ***** ** ** ***** ** 
 
Human exon 9 matched with rat exon 5: (Date of alignment 11.09.17) 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon9       GTTCCCTCCCCATATGGTCCCACCACATCATACGCTACACACGACGGGCATTCCGCATCC 60 
rat_exon5      GTTCCCTCCCCACATGGTCCCTCCCCATCACACTCTGCACACGACCGGAATCCCCCACCC 60 
               ************ ******** ** ***** ** ** ******** ** ** ** ** ** 
 
hu_exon9       GGCCATAGTCACACCAACAGTCAAACAGGAATCGTCCCAGAGTGATGTCGGCTCACTCCA 120 
rat_exon5      GGCCATTGTCACACCGACAGTCAAGCAGGAGTCCTCACAGAGTGACGTCGGCTCACTCCA 120 
               ****** ******** ******** ***** ** ** ******** ************** 
 
hu_exon9       TAGTTC 126 
rat_exon5      TAGCTC 126 
               *** ** 
 
Human exon 10 matched with rat exon 6: (Date of alignment 11.09.17) 
LUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon10      AAAGCATCAGGACTCCAAAAAGGAAGAAGAAAAGAAGAAGCCCCACATAAAGAAACCTCT 60 
rat_exon6      AAAGCATCAGGACTCCAAGAAGGAAGAAGAGAAGAAAAAGCCCCACATAAAGAAGCCCCT 60 
               ****************** *********** ***** ***************** ** ** 
 
hu_exon10      TAATGCATTCATGTTGTATATGAAGGAAATGAGAGCAAAGGTCGTAGCTGAGTGCACGTT 120 
rat_exon6      TAATGCATTCATGTTGTATATGAAGGAGATGAGAGCGAAGGTGGTGGCTGAGTGCACATT 120 
               *************************** ******** ***** ** *********** ** 
 
hu_exon10      GAAAGAAAGCGCGGCCATCAACCAGATCCTTGGGCGGAGG 160 
rat_exon6      GAAAGAGAGTGCAGCCATCAACCAGATCCTCGGGCGCAGG 160 
               ****** ** ** ***************** ***** *** 
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Human exon 11 matched with rat exon 7: (Date of alignment 11.09.17) 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon11      TGGCATGCACTGTCCAGAGAAGAGCAAGCGAAATACTACGAGCTGGCCCGGAAGGAGCGA 60 
rat_exon7      TGGCACGCCCTGTCCAGGGAAGAACAGGCAAAGTACTACGAGCTAGCCCGGAAGGAACGA 60 
               ***** ** ******** ***** ** ** ** *********** *********** *** 
 
hu_exon11      CAGCTTCATATGCAACTGTACCCCGGCTGGTCCGCGCGGGATAACTAT 108 
rat_exon7      CAGCTTCACATGCAGCTGTACCCTGGCTGGTCTGCACGGGATAACTAT 108 
               ******** ***** ******** ******** ** ************ 
 
 
 
Human exon 12 matched with rat exon 8: (Date of alignment 11.09.17) 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
Hu_exon12      GGAAAGAAGAAGAAGAGGAAAAGGGACAAGCAGCCGGGAGAGACCAATG 49 
rat_exon8      GGAAAGAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATG 49 
               ***************** ***** ************** ********** 
 
Alignment between human exon 13 and new novel rat exon ‘8b’: (Date of alignment 
01.07.18) 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
Rat8b     AACACAGCGAATGTTTCCTAAATCCTTGCCTTTCGCTTCCTCCGATCACAG 51 
HU13      AACACAGCGAATGTTTCCTAAATCCTTGCCTTTCACTTCCTCCGATTACAG 51 
          ********************************** *********** **** 
 
Alignment between human exon 14 and new novel rat exon ‘8c’: (Date of alignment 
01.07.18) 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
Rat8c     ACCTGAGCGCTCCTAAGAAATGCCGAGCGCGCTTTGGCCTTGATCAACAGAATAACTGGT 60 
HU14      ACCTGAGCGCTCCTAAGAAATGCCGAGCGCGCTTTGGCCTTGATCAACAGAATAACTGGT 60 
          ************************************************************ 
 
C68c      GCGGCCCCTGCAG 73 
HU14      GCGGCCCTTGCAG 73 
          ******* ***** 
 
 
 
Human exon15 matched with rat exon 9: (Date of alignment 11.09.17) 
 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon13      ATGCAAATACTCCAAAGAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGT 60 
rat_exon9      ATGCAAATACTCCAAAGAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGT 60 
               ************************************************************ 
 
hu_exon13      GCAAACCGTGCAG 73 
rat_exon9      GCAAACCCTGCAG 73 
               ******* ***** 
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Alignment between human exon 13 and new novel rat exon ‘9b’: (Date of alignment 
01.07.18) 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
Rat9b      TCTTTGAATTTGGAATATTAAGATG 25 
HU16       TCTTTGAATTTGGAATATTACAATG 25 
           ********************  *** 
 
 
Human exon17 matched with rat exon 10: (Date of alignment 11.09.17) 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
hu_exon14       GAGAAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGCCTCAGCCCACCCTC 60 
rat_exon10      GAGAAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGCCTCAGCCCACCCTC 60 
                ************************************************************ 
 
hu_exon14       TTCAGATGGAAGCTTACTAGATTCGCCTCCCCCCTCCCCGAACCTGCTAGGCTCCCCTCC 120 
rat_exon10      TTCAGATGGAAGCTTACTAGACTCACCTCCCCCCTCACCGCATCTGCTAGGCTCCCCTCC 120 
                ********************* ** *********** *** * ***************** 
 
hu_exon14       CCGAGACGCCAAGTCACAGACTGAGCAGACCCAGCCTCTGTCGCTGTCCCTGAAGCCCGA 180 
rat_exon10      CCAAGACGCCAAGTCACAGACTGAGCAGACACAGCCGCTCTCGCTGTCCCTGAAGCCTGA 180 
                ** *************************** ***** ** ***************** ** 
 
hu_exon14       CCCCCTGGCCCACCTGTCCATGATGCCTCCGCCACCCGCCCTCCTGCTCGCTGAGGCCAC 240 
rat_exon10      TCCTCTGGCCCACCTGTCCATGATGCCTCCACCACCCGCGCTCCTGCTGGCTGAAGCTGC 240 
                 ** ************************** ******** ******** ***** **  * 
 
hu_exon14       ---CCACAAGGCCTCCGCCCTCTGTCCCAACGGGGCCCTGGACCTGCCCCCAGCCGCTTT 297 
rat_exon10      CCACGGCAAGGCCTCTGCCCTCTGTCCCAACGGGGCCCTGGACCTGCCACCTGCCACTTT 300 
                   *  ********* ******************************** ** *** **** 
 
hu_exon14       GCAGCCTGCC---GCCCCCTCCTCATCAATTGCACAGCCGTCGACTTCTTCCTTACATTC 354 
rat_exon10      GCAGCCGTCCATGGTCCCTTCCTCATCGCTCGCACAACCATCAACTTCTTCCTTACATTC 360 
                ******  **   * *** ********  * ***** ** ** ***************** 
 
hu_exon14       CCACAGCTCCCTGGCCGGGACCCAGCCCCAGCCGCTGTCGCTCGTCACCAAGTCTTTAGA 414 
rat_exon10      CCACAACTCGCTGGCTGGGACGCAACCCCAGCCTCTGTCTCTGGTGACCAAGTCTTTAGA 420 
                ***** *** ***** ***** ** ******** ***** ** ** ************** 
 
hu_exon14       ATAGCTTTAGCGTCGTGAACCCCGCTGCTTTGTTTAT-GGTTTTGTTTCACTTTTCTTAA 473 
rat_exon10      ATAGCTTCGCCTCCTCGTCTTCCGTGCCCCTGCTTGATTGAAGTGTTTCCTTCTGGTTCT 480 
                *******   *  *  *    ***   *  ** **    *   ******  * *  **   
 
hu_exon14       TTTGCCCCCCACCCCCACCTTGAAAGGTTTTGTTTTGTACTCTCTTAATTTTGTGCCATG 533 
rat_exon10      TGGTTCGCCCTTCCCCCGCTTGGAAAGCCTTTTTTCTTGTTCTTTAATTTTGTGCCACTG 540 
                *    * ***  ****  **** ** *  ** ***  *  *** * * ***    *  ** 
 
hu_exon14       TGGCTACATTAGTTGATGTTTATCGAGTTCATTGGTCAATATTTGACCCATTCTTATTTC 593 
rat_exon10      TGGCTACATGAGTTAATGTTTATGGAGTTCATTGGTCAATATTTGACCCATTCTTATTTC 600 
                ********* **** ******** ************************************ 
 
hu_exon14       AATTTCTCCTTTTAAATATGTAGATGAGAGAAGAACCTCATGATTCTACCAAAATTTTTA 653 
rat_exon10      AATTTCTCCTTTTAAATATGTAGATGAGAG--AAACCTCATGATTCTACCAAAATTTTTA 658 
                ******************************   *************************** 
 
hu_exon14       TCAACAGCTGTTTAAAGTCTTTGTAGCGTTTAAAAAA-------TATATATATATACATA 706 
rat_exon10      TCAACAGCTGTTTAAAGTCTTTGTAGCGTTTAAAAAAATATATAAATATATATATACATA 718 
                *************************************        *************** 
 
hu_exon14       ACTGTTATGTAGTTCGGATAGCTTAGTTTTAAAAGACTGATTAAAAAACAAAAAGAAAAA 766 
rat_exon10      ACTGTTATGTAGTTCGGATAGCTTAGTTTTAAAAGACTGATTTAAGGAACAAAAAGAAAA 778 
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                ****************************************** **  *  ****  **** 
 
hu_exon14       AA----------AAGCAATTTTGAAGCAGCCCTCCAGAAGGAGTTGGTTCTGTATTATTT 816 
rat_exon10      AGAAAAGAGAGAGAAGCAACTTTGAAGCACCCTCCAGAAGGAGTTGGTTCTGTATTATTT 838 
                *            *   *  **  *    ******************************* 
 
hu_exon14       GTATTAAATACGAGCTTGCGAACCAATCATTTTACATCTGGTTTTTAAACCGTAAGGGCA 876 
rat_exon10      GTATTAAATACGAGCTTGCGAACCAATCATTTCCATCTTGGTATTTAAACCGCGAGGGCA 898 
                ********************************      **** *********  ****** 
 
hu_exon14       CCATGAATGCAGTGCCGTTACTTTTTTTTTTTT---TTTCTGTGTGAAACAACTCTTATT 933 
rat_exon10      CGATGAATGCAGTGCCGTTTCTTTCTTTCTTTTTTCCTCCCATGTGAAACAACTTTTATT 958 
                * ***************** **** *** ****    * *  ************ ***** 
 
hu_exon14       GTGATGTTACTTGTTATTGTTTAAATGTACAGAAACAAAGGGTAAAAATGTGTTAATATA 993 
rat_exon10      GTGATGTTACTTGTTATTGTTTAAATGTACAGAAACAAAGGGTTAAAATGTGTTAATATA 1018 
                ******************************************* **************** 
 
hu_exon14       CCTTGTTCCATGGTGTTGTTCTTTTGGGGGGAGGGGACGCTACTCAACACTTAATAGAAT 1053 
rat_exon10      CCTTTTTCCATGGTGTTGTTCTTTTTGGGGGGAGGGGACGCTACTCAACATGAAT--GGA 1076 
                **** ******************** *****  ***          *   * ***      
 
hu_exon14       CACAACGCTGTTGGGCCAGTAGTATTTATTGCTTTAGAGATTGCTTGTCGTACCTGTAT- 1112 
rat_exon10      ATCAACACTGTTGGACCAGTAGTATTTATTACTTTAGAGGTTGCTTGTCCGTACCTGTCC 1136 
                  **** ******* *************** ******** *********    *       
 
hu_exon14       G-TCGTCCCTTTTTAAATATGTTTTCCTTTTTCTTGAAACTGTATAAAGTTTTTTTCCCC 1171 
rat_exon10      GTCCGTCCAATTTTAAATATTGTTTCCCTTTTTTTTTTGAAACTGTATAAAGTCAACCCC 1196 
                *  *****  **********  ***** **** **           *     *   **** 
 
hu_exon14       CTTAGCATAAGCATCTTATATATAACAACTCATTTGTACAAGGTTTTTAAGTTTATATAT 1231 
rat_exon10      CCCAACATAAGCATCTTATATACAACAACTCATTTGTACAAGGTTTTTAAGTTTATATAT 1256 
                *  * ***************** ************************************* 
 
hu_exon14       AAAATGTGTATATATATTTTTGTTTCCCCTTTTTGACTT-----------TTTTTTTTCT 1280 
rat_exon10      AAATTGTGTATATATTTTTTTGTTTCCTTTTCTTGACTTTTCGTTTGTTTGTTTGTTTCT 1316 
                *** *********** ***********  ** *******            *** ***** 
 
hu_exon14       GTATGAAACCCAGATGTCACCAAATGGACATTAATAGTTGCATTAAGGATCAGTAGCATT 1340 
rat_exon10      GTATAAAACCCAGATGCCACCAAATGGACATTGATAGCTGCATTAAGGATCAGTAGCATT 1376 
                **** *********** *************** **** ********************** 
 
hu_exon14       AACAAAAGTTGCTTTAAAAGCCATTATGTAAAACAAGACTTGAAAATGAGTGAGGGAATT 1400 
rat_exon10      AACAAAAGTTGCTTTAAAAGCCATTACGTAAAACAAGACTTGAACATTAGCGAGAGGGTC 1436 
                ************************** ***************** ** ** *** *  *  
 
hu_exon14       TTAGCGACACTGTCTGAGCAGCAGTGGGAACCATCTTCGTTTCCCCTTTGAACTCCCAGT 1460 
rat_exon10      GAGCAGAGCAGCCGTGGGAA----------CCA-CCCCGTTTCCCCTTGGACCTCCTAGT 1485 
                     **       ** * *          *** *  *********** ** **** *** 
 
hu_exon14       GGGATGCCCTACCCTGCGCCCTTAGGACCCGGACTGACCGTGTACAAA--ACTTTACGTG 1518 
rat_exon10      C-----AATTACCCTGTGCTCTTAGAACATGGACTGACCGTGTGCAAAACTTTTTATGTG 1540 
                         ******* ** ***** **  ************* ****    **** *** 
 
hu_exon14       CCAAAATTCTCAGTGAATTTAGCTTTCTCCCT-CTTTTTGATGCTGTAATTTTTGTTCAT 1577 
rat_exon10      CCAAAATTCTCAGTGACTTTAGCTTTCTCCCTCCTTTTTGATGCCGTACTTTCTGTTCGC 1600 
                **************** *************** *********** *** *** *****   
 
hu_exon14       CATGTTTTGCTGTGATGTTACATAGGTAGATTTGTATGTAGTTTTAATGTCACCTATAAC 1637 
rat_exon10      CATGTTTTGCTGTGATGTTACATAGATAGATTTGTATGTAGTTTTAATGTCACCTATAAC 1660 
                ************************* ********************************** 
 
hu_exon14       AAAATGTGTTTGGTAGCAGATTGTCCAGAAAGCATTTTAAATGAAGAGGTATAAACCCTT 1697 
rat_exon10      AAAATGTGTTTGGTAGCAGACTGTCCAGAAAGCATTTTAAATGAAGAGGTCTAAACCCTT 1720 
                ******************** ***************************** ********* 
 
hu_exon14       AAGGGCCAAAAT-TCTGTATATTAGATTACTCTTAAAC---------------------- 1734 
rat_exon10      AAGGGCCAAAAATTCTGTATATTAGATTACTCTTAAAATGAAAAAGAAAAAAAGTAAAAA 1780 
                ***********  ************************                        
 
hu_exon14       ----GAAAAACCAGCTGCCGCTTTTATGTACACATATTACATACGAGTAGGCAGCAGACT 1790 
rat_exon10      AAAAAAAAACCCAGCTGCCGCTTCTGTGTACAAGTATGACATACGAGTAGGTAGCGAACT 1840 
                     **** ************* * ******  *** ************* ***  *** 
 
hu_exon14       TTAAAAATAAAAAAAACCTAGGCATGTTGATGTTGCAAAATGCTGTATAAAGCTGAAACC 1850 
rat_exon10      TTAAA-AACAAGAGAACCTAGGCATGCCGATGTTGTAAAATGCTGTATAAAGCCGAGACC 1899 
                ***** *  ** * ************  ******* ***************** ** *** 
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hu_exon14       TGTTCATTCAGTGCCATTGTAGTTGACATGAAGCGATTGTAAAACTGTCTCCGATTTTTC 1910 
rat_exon10      TGTCTTTTCAGTGCCATCGTAGTTGACATGAAGCGATTGTAAAACTGTCTCCGGTTTTC- 1958 
                ***   *********** *********************************** ****   
 
hu_exon14       TCTGGTTTATTAAAATGCTAACTATAACA------------------------------- 1939 
rat_exon10      TCTGGTTTATTAAAATGCTAACTATAACAATTTTTTTTTGTGAATACTTTGAATGTTTCC 2018 
                *****************************                                
 
hu_exon14       ------------------------------------------------------------ 1939 
rat_exon10      TAACAGTTGTGGTGTTACCGTTCTGTTTGATGCTTATTCCAAGTTCATTTTTGGATGGTT 2078 
                                                                             
 
hu_exon14       ------------------------------------------------------------ 1939 
rat_exon10      TGGAAGCCATTTTGTAATGAATAAATGTCCATGCTGTACAGTATCTGTAGCATGCCGTTC 2138 
                                                                             
 
hu_exon14       ------------------------------- 1939 
rat_exon10      TGGATTAATAAAAGCAACTTAGTATGTGCAG 2169 
 
 
9.5 Alignment results between Tcf7l2 protein coding (Expected) and splice 
variants A (composite) in pancreatic β cells.  
 
(Exon7_Exon8_Exon9_Exon10) 
 
CLUSTAL O (1.2.4) multiple sequence alignment  
 
 
Composite      ------------------------------------------------------------ 0 
expected       GCGCAGGTGGCACGCCCTGTCCAGGGAAGAACAGGCAAAGTACTACGAGCTAGCCCGGAA 60 
                                                                            
 
Composite      ---------------------------------CTGGTTTGCACGGGATAACTATGGAAA 27 
expected       GGAACGACAGCTTCACATGCAGCTGTACCCTGGCTGGTCTGCACGGGATAACTATGGAAA 120 
                                                ***** ********************* 
 
Composite      GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGATGCAAATACTCCAAA 87 
expected       GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGATGCAAATACTCCAAA 180 
               ************************************************************ 
 
Composite      GAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCAGGAG 147 
expected       GAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCAGGAG 240 
               ************************************************************ 
 
 
Composite      AAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAGGCCCCTGCAAC-------------- 193 
expected       AAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGCCTCAGCCCACCCTCTTC 300 
               *************************************  ****  *               
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9.6 Alignment results between Tcf7l2 protein coding (Expected) and splice 
variants B (composite) in pancreatic β cells. 
 
(Exon7_Exon8_Exon10) 
 
CLUSTAL O (1.2.4) multiple sequence alignment 
 
 
Composite:      ------------------------------------------------------------ 0 
Expected        TGGCACGCCCTGTCCAGGGAAGAACAGGCAAAGTACTACGAGCTAGCCCGGAAGGAACGA 60 
                                                                             
 
Composite:      ------------------------TTCTGGTCTGCACGGGATAACTATGGAAAGAAGAAG 36 
Expected        CAGCTTCACATGCAGCTGTACCCTGGCTGGTCTGCACGGGATAACTATGGAAAGAAGAAG 120 
                                          ********************************** 
 
Composite:      AAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATG----------------------- 88 
Expected        AAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGATGCAAATACTCCAAAGAAGTGT 180 
                *************************************                         
 
Composite:      --------------------------------------------------GAGAAAAAAA 88 
Expected        CGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCAGGAGAAAAAAA 240 
                                                                  **********           
 
Composite:      AAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGC------------------------ 119 
Expected        AAGTGCGTTCGCTACATACAAGGTGAAGGCAGCTGCCTCAGCCCACCCTCTTCAGATGGA 300 
                ************************************                         
 
Composite:      ------------------------------------------------------------ 119 
Expected        AGCTTACTAGACTCACCTCCCCCCTCACCGCATCTGCTAGGCTCCCCTCCCCAAGACGCC 360 
 
 
 
9.7 Alignment results between Tcf7l2 protein coding (Expected) and splice 
variants C (composite) in pancreatic β cells. 
 
(Exon7_Exon8_Exon9_Exon9b_Exon10) 
CLUSTAL O (1.2.4) multiple sequence alignment 
 
 
Composite      ------------------------------------------------------------ 0 
expected       GCGCAGGTGGCACGCCCTGTCCAGGGAAGAACAGGCAAAGTACTACGAGCTAGCCCGGAA 60 
                                                                            
 
Composite      --------------------------------TCTGGTCTGCACGGGATAACTATGGAAA 28 
expected       GGAACGACAGCTTCACATGCAGCTGTACCCTGGCTGGTCTGCACGGGATAACTATGGAAA 120 
                                                *************************** 
 
Composite      GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGATGCAAATACTCCAAA 88 
expected       GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGATGCAAATACTCCAAA 180 
               ************************************************************ 
 
Composite      GAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCAGTCT 148 
expected       GAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCAG--- 240 
               *********************************************************    
 
Composite      TTGAATTTGGAATATTATGATGGAGAAAAAAAAAGGGCGTTCGCTACATACAAGGTGAAG 208 
expected       ---------------------GGAGAAAAAAAAAGTGCGTTCGCTACATACAAGGTGAAG 275 
                                    *************************************** 
 
Composite      GCAGCTGCAACA------------------------------------------------ 220 
expected       GCAGCTGCCTCAGCCCACCCTCTTCAGATGGAAGCTTACTAGACTCACCTCCCCCCTCAC 335 
               ********  **                                                 
 
Composite      ------------------------------------------------------------ 220 
expected       CGCATCTGCTAGGCTCCCCTCCCCAAGACGCCAAGTCACAGACTGAGCAGACACAGCCGC 395 
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9.8 Alignment results between Tcf7l2 protein coding (Expected) and splice 
variants D (composite) in pancreatic β cells. 
 
(Exon7_Exon8_Exon8b_Exon8c _Exon9_Exon9b_Exon10) 
 
CLUSTAL O (1.2.4) multiple sequence alignment 
 
 
Composite      ------------------------------------------------------------ 0 
expected       GCGCAGGTGGCACGCCCTGTCCAGGGAAGAACAGGCAAAGTACTACGAGCTAGCCCGGAA 60 
                                                                            
 
Composite      -------------------------------TTCTGGTCTGCACGGGATAACTATGGAAA 29 
expected       GGAACGACAGCTTCACATGCAGCTGTACCCTGGCTGGTCTGCACGGGATAACTATGGAAA 120 
                                                *************************** 
 
Composite      GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATGAACACAGCGAATGTTT 89 
expected       GAAGAAGAAGAGAAAAAGAGACAAGCAGCCGGGGGAGACCAATG---------------- 162 
               ********************************************                   
 
Composite      CCTAAATCCTTGCCTTTCGCTTCCTCCGATCACAGACCTGAGCGCTCCTAAGAAATGCCG 149 
expected       ------------------------------------------------------------ 162 
                                                                            
 
Composite      AGCGCGCTTTGGCCTTGATCAACAGAATAACTGGTGCGGCCCCTGCAGATGCAAATACTC 209 
expected       ------------------------------------------------ATGCAAATACTC 176 
                                                               ************ 
 
Composite      CAAAGAACTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCA 269 
expected       CAAAGAAGTGTCGGGCACTGTTCGGGCTTGACCGACAGACTTTATGGTGCAAACCCTGCA 236 
               ******* **************************************************** 
 
Composite      GCCTTTGAATTTGGAATATTATGATGGAGAAAAAAAAAGTG------------------- 310 
expected       -------------------------GGAGAAAAAAAAAGTGCGTTCGCTACATACAAGGT 296 
                                        ****************                               
 
Composite      ------------------------------------------------------------ 310 
expected       CTTCAGATGGAAGCTTACTAGACTCACCTCCCCCCTCACCGCATCTGCTAGGCTCCCCTC 356 
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9.9 A Summary of rat Tcf7l2 Splice Variants Analysis in INS1 cell. 
 
Sample 
code 
Rat 
Tcf7l2 
primers 
Estimated 
band size 
based on 
the gel 
(bp) 
Sequence 
similarity 
with Tcf7l2 
(Blastn 
Result) 
Exon Position 
A1 1F and 
2R 
110 
(Sequence 
length-114 
bp) 
similar 
Exon1-exon2 
A2 1F and 
2R 
350 Sequencing 
quality was 
good. Blastn 
results shown 
Rattus 
bacterial 
Prosc.; need 
to purify 
bands further 
to identify. 
Not applicable 
 
A3 1F and 
2R 
450 Sequence 
quality was 
poor. Blastn 
results shown 
no sequence 
similarities 
with Tcf7l2. 
Not applicable 
A4 1F and 
2R 
620 Sequence 
had 
similarities 
with 
Streptomyces 
strain. 
Not applicable 
A5 7F and 
10R 
110 
(Sequence 
length 119 
bp) 
Sequence 
quality was 
good and 
exact 
matched with 
Tcf7l2. 
Exon7_Exon8_Exon 
10 
A6 7F and 
10R 
210 
(Sequence 
length 220 
bp) 
Sequence 
quality was 
good and 
exact 
matched with 
Tcf7l2. 
Exon7_Exon 
8_Exon 
9_Exon9b_Exon 10 
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A7 7F and 
10R 
280 
(Sequence 
length 221 
bp) 
Sequence 
quality was 
good and 
exact 
matched with 
Tcf7l2. 
Exon7_Exon 
8_Exon 
9_Exon9b_Exon10 
A8 7F and 
10R 
340 
(Sequence 
length 342 
bp) 
Sequence 
quality was 
good and 
exact 
matched with 
Tcf7l2. 
Exon7 (starts with 
primer 
seq)_Exon8_Exon 
8b_Exon 
8c_Exon9_Exon 
9b_Exon10 
 
 
9.10 Analysis of Tcf7l2 splice variants on Con vs GLT. 
 
Sample 
(Tcf7l2); con-C, 
GLT- G 
Estimated band 
size based on 
the gel (bp)  
Sequence 
similarity with 
Tcf7 (Blastn 
Result) 
Exon 
Position  
C1 110 bp 
(Sequence 
length 119 bp) 
similar 
Exon 7 
(though only  
2bp) – exon 8 
– exon 10  
 
C2 180/190 
(Sequence 
length 120 bp) 
similar 
Exon 7 
(though only  
2bp) – exon 8 
– exon 10  
C3 190/200 
(Sequence 
length 220 bp) 
similar 
Exon 7 
(though only 
2bp) – exon 8 
- exon9-
exon9b-exon 
10 
 
C4 205/210 Sequencing 
quality too poor to 
tell but has region 
of exon8; need to 
purify bands 
further to identify. 
Unknown. 
C5 240/250 Sequencing 
quality too poor to 
tell but has region 
Unknown. 
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of exon8b; need 
to purify bands 
further to identify. 
C6 290 (Sequence 
length 310 bp)/ 
Exon 10 did not 
go through the 
reverse primer. 
similar Exon 7 
(though only  
2bp) – exon 8 
–exon8b-
exon8c- 
exon9-
exon9bexon 
10 (part of e-
10; reverse 
primer seq 
missing 
C7 350 Sequencing 
quality too poor to 
tell but has region 
of exon8; need to 
purify bands 
further to identify. 
Unknown. 
C8 490 Sequence quality 
too low to tell 
anything. 
Unknown. 
G1 100/105 
(Sequence 
length 119 bp) 
 
Similar to C1 
Exon 7 
(though only 
2bp) – exon 8 
– exon 10 ie 
is lacking 
exon 9 
 
G2 190-Predicted 
Band Size 
(Sequence 
length 193 bp) 
 
Similar Exon 7 
(though only 
2bp) – exon 
8-exon9-exon 
10 
G3 200/205 
(Sequence 
length 219 bp) 
 
Identical to C3 Exon 7 
(though only 
2bp) – exon 
8- exon9-
exon9b-exon 
10 
G4 270 Sequencing 
quality too poor to 
tell but has region 
of exon8; need to 
purify bands 
Unknown. 
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further to identify 
(may be 
equivalent to C5 
based on prod 
length and that 
clean sequence 
in both was 
exon8). 
G5 300 Sequencing 
quality too poor to 
tell but has region 
of exon8; need to 
purify bands 
further to identify 
(may be same 
band as G4). 
Unknown. 
G6 300/310 
(Sequence 
length 340 bp) 
 
Identical to C6, 
except that 
exon10 goes 
through to rev 
primer 
Exon 7 
(though only 
2bp) – exon 8 
–exon8b-
exon8c- 
exon9-
exon9b-exon 
10   
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9.11 Tcf7l2 splice variantrs on high sugar and free fatty acids and 
compare them with controls. A) Region 1 and B) Region 2 
 
A) 
 
B) 
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